0001104659-24-077866.txt : 20240705 0001104659-24-077866.hdr.sgml : 20240705 20240703200108 ACCESSION NUMBER: 0001104659-24-077866 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240628 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240705 DATE AS OF CHANGE: 20240703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cytosorbents Corp CENTRAL INDEX KEY: 0001175151 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 980373793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36792 FILM NUMBER: 241101390 BUSINESS ADDRESS: STREET 1: 305 COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 973-329-8885 MAIL ADDRESS: STREET 1: 305 COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: MedaSorb Technologies CORP DATE OF NAME CHANGE: 20060807 FORMER COMPANY: FORMER CONFORMED NAME: GILDER ENTERPRISES INC DATE OF NAME CHANGE: 20020611 8-K 1 tm2418904d1_8k.htm FORM 8-K
false 0001175151 0001175151 2024-06-28 2024-06-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): June 28, 2024

 

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter) 

 

Delaware   001-36792   98-0373793
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (I.R.S. Employer Identification No.)

 

305 College Road East

Princeton, New Jersey

08540
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (732) 329-8885

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common stock, par value $0.001 per share CTSO The Nasdaq Stock Market LLC (Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

¨

 

 

 

 

 

Item 1.01       Entry into a Material Definitive Agreement

 

On June 28, 2024 (the “Closing Date”), CytoSorbents Corporation, a Delaware corporation (the “Company”), along with CytoSorbents Medical Inc., a Delaware corporation and wholly owned subsidiary of the Company (“CytoSorbents Medical” and, together with the Company, the “Borrower”), entered into a Loan and Security Agreement (as amended, supplemented, restated or otherwise modified as of the date hereof and from time to time, the “Loan and Security Agreement”) with Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (“Avenue”), Avenue Venture Opportunities Fund II, L.P., a Delaware limited partnership (“Avenue 2” and, together with Avenue, the “Lenders”), and Avenue Capital Management II, L.P., a Delaware limited partnership (the “Administrative and Collateral Agent”).

 

Under the Loan and Security Agreement, the Lenders have agreed to loan to the Borrower up to an aggregate of $20 million, to be disbursed in two tranches: (1) one tranche of $15 million (“Growth Capital Loan Tranche 1”) on the Closing Date, with $4.5 million funded by Avenue and $10.5 million funded by Avenue 2, of which $10 million is available to the Borrower on the Closing Date and $5,000,000 constitutes restricted cash subject to release to the Borrower prior to March 31, 2025, provided certain conditions are met and (2) a second tranche of up to $5 million, which may be disbursed at the Borrower’s request between July 1, 2025 and December 31, 2025, provided certain conditions are met (“Growth Capital Loan Tranche 2” and together with Growth Capital Loan Tranche 1, the “Growth Capital Loans” or the “Commitment”). The proceeds from the Commitment will be used for working capital purposes and to fund general business requirements in accordance with the terms of the Loan and Security Agreement. Each Growth Capital Loan shall bear interest at a variable rate per annum equal to the greater of (A) the Prime Rate (as defined in the Loan and Security Agreement) plus five percent (5.00%) and (B) thirteen and one half percent (13.50%).

 

Commencing on the first calendar day of the calendar month after a Growth Capital Loan is made, the Borrower shall make monthly payments during the term of each Growth Capital Loan of interest only during the initial 24 month period following the Closing Date (as may be extended to the 30 months anniversary of the Closing Date upon satisfaction of certain conditions) and thereafter to maturity in equal monthly installments of principal plus accrued and unpaid interest. All unpaid principal and accrued and unpaid interest shall be due and payable in full on July 1, 2027; provided, however that if the Borrower draws the full amount of Growth Capital Loan Tranche 2 by December 31, 2025, all unpaid principal and accrued and unpaid interest shall be due and payable in full by January 1, 2028. In addition, the Loan and Security Agreement requires the Borrower to pay a non-refundable commitment fee equal to 1.00% of the principal amount of each Growth Capital Loan, due and payable on the Closing Date, of which $100,000 was paid by the Borrower to Avenue as an advance deposit prior to the Closing Date. The Capital Growth Loans shall be evidenced by one or more secured promissory notes issued to the Lenders by the Borrower. If the Borrower elects to prepay the Growth Capital Loan(s) pursuant to the terms of the Loan and Security Agreement, it will owe a prepayment fee to the Lenders, as follows: (1) for a prepayment made on or after the funding date of a Growth Capital Loan through and including the first anniversary of such funding date, an amount equal to 3.00% of the principal amount of such Growth Capital Loan prepaid; (2) for a prepayment made after the first anniversary of the funding date of a Growth Capital Loan through and including the second anniversary of such funding date, an amount equal to 2.00% of the principal amount of such Growth Capital Loan prepaid; and (3) for a prepayment made any time after the second anniversary of the funding date of a Growth Capital Loan, an amount equal to 1.00% of the principal amount of such Growth Capital Loan prepaid.

 

Events of default which may cause repayment of the Commitment to be accelerated include, among other customary events of default, (1) non-payment of any obligation when due, (2) the failure to perform any obligation required under the Loan and Security Agreement and to cure such default within a reasonable time frame, (3) the occurrence of any circumstance that has a Material Adverse Effect (as defined in the Loan and Security Agreement), (4) default beyond any applicable grace period or cure under any other agreement involving the borrowing of money in excess of the Threshold Amount (as defined in the Loan and Security Agreement), (5) any judgment(s) singly or in the aggregate in excess of the Threshold Amount entered against the Borrower that remain unsatisfied, unvacated or unstayed for 15 days or more after entry thereof (to the extent not otherwise covered by independent third-party insurance), and (6) if the Borrower becomes insolvent or starts an insolvency proceeding or if an insolvency proceeding is brought by a third party against the Borrower and such proceeding is not dismissed or stayed within 45 days. The Loan and Security Agreement includes customary loan conditions, borrower representations and warranties, borrower affirmative covenants and borrower negative covenants for secured transactions of this type.

 

 

 

 

The Company’s and CytoSorbents Medical’s obligations under the Loan and Security Agreement are joint and several. The obligations under the Loan and Security Agreement are secured by a first priority security interest in favor of the Lenders with respect to the Borrower’s Shares (as defined in the Loan and Security Agreement) and the Borrower’s Collateral (as defined in the Loan and Security Agreement), which includes the Company’s intellectual property, pursuant to that certain Intellectual Property Security Agreement, dated as of June 28, 2024, by and between the Company and the Administrative and Collateral Agent.

 

A copy of the Loan and Security Agreement and the supplement thereto are attached as Exhibits 10.1 and 10.2, respectively, and are incorporated herein by reference. The foregoing is a summary description of the terms of the Loan and Security Agreement and does not purport to be complete.

 

As additional consideration for the Commitment, on June 28, 2024 the Company also issued each Lender a warrant instrument (each, a “Warrant”) entitling the Lenders to purchase an aggregate of 1,645,569 shares of the Company’s common stock for cash at the Exercise Price (as defined in the Warrant). The Lenders were also granted the right while the Commitment is outstanding to convert up to an aggregate of $2,000,000 of the principal amount of the outstanding Growth Capital Loans into the Company’s common stock at a conversion price of 120% of the Closing Price (as defined in the warrant) (the “Conversion Option”).

 

A copy of the form of Warrant is attached hereto as Exhibit 10.3 and is incorporated herein by reference. The foregoing is a summary description of the terms of the form of Warrant and does not purport to be complete.

 

 

Item 8.01       Other Events

 

On June 28, 2024, the Company issued a press release announcing its entry into the Loan and Security Agreement. A copy of the press release is included as Exhibit 99.1 and incorporated by reference herein.

 

Item 9.01       Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.  Description
10.1*  Loan and Security Agreement by and among the Borrower, the Lenders and the Administrative and Collateral Agent, dated June 28, 2024
10.2*  Supplement to the Loan and Security Agreement by and among the Borrower, the Lenders and the Administrative and Collateral Agent, dated June 28, 2024
10.3  Form of Warrant to Purchase Shares of Stock of CytoSorbents Corporation by and between the Company and the Lender, dated June 28, 2024
99.1  Press Release of the Company, dated June 28, 2024
104  Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

* Portions of this exhibit have been redacted in accordance with Item 601(b)(10)(iv) of Regulation S-K.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 3, 2024 CYTOSORBENTS CORPORATION
     
  By: /s/ Dr. Phillip P. Chan
  Name: Dr. Phillip P. Chan
  Title: Chief Executive Officer

 

 

 

EX-10.1 2 tm2418904d1_ex10-1.htm EXHIBIT 10.1

 

Exhibit 10.1

 

Certain portions of this exhibit have been redacted because the information is both (i) not material and (ii) the type that the registrant treats as private or confidential. Redacted information has been noted in this document with a placeholder identified by the mark “[*]”.

 

LOAN AND SECURITY AGREEMENT

 

Dated as of June 28, 2024

 

among

 

CYTOSORBENTS CORPORATION,

a Delaware corporation,

(“Parent”)

 

and

 

CYTOSORBENTS MEDICAL INC.

a Delaware corporation,

(“Medical”; and together with Parent,

jointly and severally, individually and collectively, “Borrower”)

 

and

 

AVENUE CAPITAL MANAGEMENT II, L.P.,

a Delaware limited partnership

(as administrative agent and collateral agent (in such capacity “Agent”)

 

and

 

AVENUE VENTURE OPPORTUNITIES FUND II, L.P.,

a Delaware limited partnership, (“Avenue 2“)

as a lender

 

and

 

AVENUE VENTURE OPPORTUNITIES FUND, L.P.,

a Delaware limited partnership (“Avenue“)

as a lender (in such capacity, with Avenue 2, a “Lender” and collectively, the “Lenders”)

 

 

 

LOAN AND SECURITY AGREEMENT

 

Borrower, Lenders and Agent have entered or anticipate entering into one or more transactions pursuant to which each Lender agrees to make available to Borrower a loan facility governed by the terms and conditions set forth in this document and one or more Supplements executed by Borrower, Lenders and Agent which incorporate this document by reference. Each Supplement constitutes a supplement to and forms part of this document, and will be read and construed as one with this document, so that this document and the Supplement constitute a single agreement between the parties (collectively referred to as this Agreement).

 

Accordingly, the parties agree as follows:

 

ARTICLE 1 - INTERPRETATION

 

1.1            Definitions. The terms defined in Article 10 and in the Supplement will have the meanings therein specified for purposes of this Agreement.

 

1.2            Inconsistency. In the event of any inconsistency between the provisions of any Supplement and this document, the provisions of the Supplement will be controlling for the purpose of all relevant transactions.

 

ARTICLE 2 - THE COMMITMENT AND LOANS

 

2.1            The Commitment. Subject to the terms and conditions of this Agreement, each Lender agrees to make term loans to Borrower from time to time from the Closing Date and to and including the Termination Date in an aggregate principal amount not exceeding the Commitment. The Commitment is not a revolving credit commitment, and Borrower does not have the right to repay and reborrow hereunder. The aggregate Loans requested by Borrower to be made on a single Business Day shall be for a minimum principal amount set forth in the Supplement, except to the extent the remaining Commitment is a lesser amount.

 

2.2            Notes Evidencing Loans; Repayment. Each Loan shall be evidenced by a separate Note payable to the order of each Lender of such Loan, in the total principal amount of the Loan. Principal and interest of each Loan shall be payable at the times and in the manner set forth in the Note and regularly scheduled payments thereof shall be effected by automatic debit of the appropriate funds from Borrower’s Primary Operating Account as specified in the Supplement hereto. Repayment of the Loans and payment of all other amounts owed to each Lender will be paid by Borrower in the currency in which the same has been provided (i.e., United States Dollars).

 

2.3            Procedures for Borrowing.

 

(a)             At least five (5) Business Days prior to a proposed Borrowing Date (or such lesser period of time as may be agreed upon by the Required Lenders in their sole discretion), Lender shall have received from Borrower a written request for a borrowing hereunder (a Borrowing Request). Each Borrowing Request shall be in substantially the form of Exhibit “B” to the Supplement, shall be executed by a responsible executive or financial officer of Borrower, and shall state how much is requested, and shall be accompanied by such other information and documentation as any Lender may reasonably request, including the executed Note(s) for the Loan(s) covered by the Borrowing Request.

 

(b)             No later than 1:00 p.m. Pacific Standard Time on the Borrowing Date, if Borrower has satisfied the conditions precedent in Article 4 by 9:00 a.m. Pacific Standard Time on such Borrowing Date, each Lender shall make its Loan available to Borrower in immediately available funds.

 

2.4            Interest. Except as otherwise specified in the applicable Note and/or Supplement, Basic Interest on the outstanding principal balance of each Loan shall accrue daily at the Designated Rate from the Borrowing Date. If the outstanding principal balance of such Loan is not paid at maturity, interest shall accrue at the Default Rate until paid in full, as further set forth herein.

 

2.5            Intentionally Omitted.

 

2.6            Interest Rate Calculation. Basic Interest, along with charges and fees under this Agreement and any Loan Document, shall be calculated for actual days elapsed on the basis of a 360-day year, which results in higher interest, charge or fee payments than if a 365-day year were used. In no event shall Borrower be obligated to any pay Lender interest, charges or fees at a rate in excess of the highest rate permitted by applicable law from time to time in effect.

 

1

 

 

2.7            Default Interest. Any unpaid payments in respect of the Obligations shall bear interest from their respective maturities, whether scheduled or accelerated, at the Default Rate, compounded monthly. Borrower shall pay such interest on demand.

 

2.8            Late Charges. If Borrower is late in making any scheduled payment in respect of the Obligations by more than five (5) days, then Borrower agrees to pay a late charge of five percent (5%) of the payment due, but not less than fifty dollars ($50.00) for any one such delinquent payment. This late charge shall be charged by Agent, for the ratable benefit of the Lenders, for the purpose of defraying the expenses incidental to the handling of such delinquent amounts. Borrower acknowledges that such late charge represents a reasonable sum considering all of the circumstances existing on the date of this Agreement and represents a fair and reasonable estimate of the costs that will be sustained by Lenders due to the failure of Borrower to make timely payments. Borrower further agrees that proof of actual damages would be costly and inconvenient. Such late charge shall be paid without prejudice to the right of Lenders and Agent to collect any other amounts provided to be paid or to declare a default under this Agreement or any of the other Loan Documents or from exercising any other rights and remedies of Agent for the ratable benefit of the Lenders.

 

2.9            Lender’s Records. Principal, Basic Interest and all other sums owed under any Loan Document shall be evidenced by entries in records maintained by each Lender for such purpose. Each payment on and any other credits with respect to principal, Basic Interest and all other sums outstanding under any Loan Document shall be evidenced by entries in such records. Absent manifest error, each Lender’s records shall be conclusive evidence thereof.

 

2.10          Grant of Security Interests; Filing of Financing Statements.

 

(a)            To secure the timely payment and performance of all of Borrower’s Obligations, Borrower hereby grants to Agent, for the ratable benefit of the Lenders, continuing security interests in all of the Collateral. In connection with the foregoing, Borrower authorizes Agent to prepare and file any financing statements describing the Collateral without otherwise obtaining Borrower’s signature or consent with respect to the filing of such financing statements. Such financing statements may indicate the Collateral as “all assets of the Debtor” or words of similar effect.

 

(b)             In furtherance of Borrower’s grant of the security interests in the Collateral pursuant to Section 2.10(a) above, Borrower hereby pledges and grants to Agent, for the ratable benefit of the Lenders, a security interest in all the Shares, together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights to subscribe for securities declared or granted in connection therewith, and all other cash and noncash proceeds of the foregoing, as security for the performance of the Obligations. On the Closing Date or at any time thereafter following Agent’s request, the certificate or certificates for the Shares will be delivered to the Agent, accompanied by an instrument of assignment duly executed in blank by Borrower, unless such Shares have not been certificated. To the extent required by the terms and conditions governing the Shares, Borrower shall cause the books of each entity whose Shares are part of the Collateral and any transfer agent to reflect the pledge of the Shares. Upon the occurrence and during the continuance of an Event of Default hereunder, Agent, at the direction of the Required Lenders, may effect the transfer of any securities included in the Collateral (including but not limited to the Shares) into the name of Agent and cause new certificates representing such securities to be issued in the name of Agent or its transferee(s). Borrower will execute and deliver such documents, and take or cause to be taken such actions, as Agent may reasonably request to perfect or continue the perfection of Agent’s security interest in the Shares. Except as provided in the following sentence, Borrower shall be entitled to exercise any voting rights with respect to the Shares and to give consents, waivers and ratifications in respect thereof, provided that no vote shall be cast or consent, waiver or ratification given or action taken which would constitute a violation of any of the terms of this Agreement. All such rights to vote and give consents, waivers and ratifications shall terminate upon the occurrence and continuance of an Event of Default and Agent’s, at the direction of the Required Lenders, written notice to Borrower of Agent’s intent to exercise its rights and remedies under this Agreement, including this Section 2.10(b).

 

(c)             Borrower is and shall remain absolutely and unconditionally liable for the performance of its Obligations, including, without limitation, any deficiency by reason of the failure of the Collateral to satisfy all amounts due to each Lender under any of the Loan Documents.

 

2

 

 

(d)             All Collateral pledged by Borrower under this Agreement and any Supplement shall secure the timely payment and performance of all Obligations. Except as expressly provided in this Agreement, no Collateral pledged under this Agreement or any Supplement shall be released until such time as all Obligations have been satisfied and paid in full (other than inchoate indemnity obligations).

 

ARTICLE 3 - REPRESENTATIONS AND WARRANTIES

 

Borrower represents and warrants that, except as set forth in the Supplement or the Schedule of Exceptions hereto, if any, as of the Closing Date and each Borrowing Date:

 

3.1            Due Organization. Borrower is a corporation duly organized and validly existing in good standing under the laws of the jurisdiction of its incorporation, and is duly qualified to conduct business and is in good standing in each other jurisdiction in which its business is conducted or its properties are located, except where the failure to be so qualified would not reasonably be expected to have a Material Adverse Effect.

 

3.2            Authorization, Validity and Enforceability. The execution, delivery and performance of all Loan Documents executed by Borrower are within Borrower’s powers, have been duly authorized, and are not in conflict with Borrower’s certificate of incorporation or by-laws, or the terms of any charter or other organizational document of Borrower, as amended from time to time; and all such Loan Documents constitute valid and binding obligations of Borrower, enforceable in accordance with their terms (except as may be limited by bankruptcy, insolvency and similar laws affecting the enforcement of creditors’ rights in general, and subject to general principles of equity).

 

3.3            Compliance with Applicable Laws. Borrower has complied with all licensing, permit and fictitious name requirements necessary to lawfully conduct the business in which it is engaged, and to any sales, leases or the furnishing of services by Borrower, including without limitation those requiring consumer or other disclosures, the noncompliance with which would have a Material Adverse Effect.

 

3.4            No Conflict. The execution, delivery, and performance by Borrower of all Loan Documents are not in conflict with any law, rule, regulation, order or directive, or any indenture, agreement, or undertaking to which Borrower is a party or by which Borrower may be bound or affected, except where such conflict with respect to such indenture, agreement, or undertaking would not reasonably be expected to have a Material Adverse Effect. Without limiting the generality of the foregoing, the issuance of the Warrant and the grant of registration rights, if any, in connection therewith do not violate any agreement or instrument by which Borrower is bound or require the consent of any holders of Borrower’s securities other than consents which have been obtained prior to the Closing Date.

 

3.5            No Litigation, Claims or Proceedings. Except as set forth in the Schedule of Exceptions hereto, here is no litigation, tax claim, proceeding or dispute pending, or, to the knowledge of Borrower, threatened against or affecting Borrower, its property or the conduct of its business, in each case where an adverse decision would reasonably be expected to result in a Material Adverse Effect or in damages in excess of the Threshold Amount.

 

3.6            Correctness of Financial Statements. Borrower’s financial statements which have been delivered to Lender fairly and accurately, in all material respects, reflect Borrower’s financial condition in accordance with GAAP as of the latest date of such financial statements; and, since that date there has been no Material Adverse Change.

 

3.7            No Subsidiaries. As of the Closing Date, Parent is not a majority owner of or in a control relationship with any other business entity, except for those listed on Schedule 3.7.

 

3.8            Environmental Matters. To its knowledge after reasonable inquiry, Borrower has concluded that Borrower is in compliance with Environmental Laws, except to the extent a failure to be in such compliance would not reasonably be expected to have a Material Adverse Effect.

 

3.9            No Event of Default. No Default or Event of Default has occurred and is continuing.

 

3.10          Full Disclosure. None of the representations or warranties made by Borrower in the Loan Documents as of the date such representations and warranties are made or deemed made, and none of the written statements contained in any exhibit, report, statement or certificate furnished by or on behalf of Borrower in connection with the Loan Documents (including disclosure materials delivered by or on behalf of Borrower to Lenders prior to the Closing Date or pursuant to Section 5.2 hereof), taken as a whole, contains any untrue statement of a material fact or omits any material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they are made, not misleading as of the time when made or delivered (it being recognized by Agent that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).

 

3

 

 

3.11          Specific Representations Regarding Collateral.

 

(a)             Title. Except for the security interests created by this Agreement and Permitted Liens, (i) Borrower is the unconditional legal and beneficial owner of the Collateral, and (ii) the Collateral is genuine and subject to no Liens. There exist no prior assignments or encumbrances of record with the U.S. Patent and Trademark Office or U.S. Copyright Office affecting any Collateral in favor of any third party, other than Permitted Liens.

 

(b)             Rights to Payment. The names of the obligors, amount owing to Borrower, due dates and all other information with respect to the Rights to Payment are correctly stated in all material respects in all Records relating to the Rights to Payment. Borrower further represents and warrants, to its knowledge, that each Person appearing to be obligated on a Right to Payment has authority and capacity to contract and is bound as it appears to be.

 

(c)             Location of Collateral. As of the Closing Date, Borrower’s chief executive office, Inventory, Records, Equipment, and any other offices or places of business are located at the address(es) shown on the Supplement.

 

(d)             Business Names. Other than its full corporate name or as disclosed to the Agent from time to time, Borrower has not conducted business using any trade names or fictitious business names except as shown on the Supplement.

 

3.12         Copyrights, Patents, Trademarks and Licenses.

 

(a)             Borrower owns or is licensed or otherwise has the right to use all of the material patents, trademarks, service marks, trade names, copyrights, contractual franchises, authorizations and other similar rights that are reasonably necessary for the operation of its business, without known conflict with the rights of any other Person.

 

(b)             To Borrower’s knowledge, no slogan or other advertising device, product, process, method, substance, part or other material now employed, or now contemplated to be employed, by Borrower infringes upon any rights held by any other Person.

 

(c)             No claim or litigation regarding any of the foregoing is pending or, to Borrower’s knowledge, threatened, and, to Borrower’s knowledge, no patent, invention, device, application, principle or any statute, law, rule, regulation, standard or code is pending or proposed which, in either case, could reasonably be expected to have a Material Adverse Effect.

 

3.13          Regulatory Compliance. Borrower has met the minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. No event has occurred resulting from Borrower’s failure to comply with ERISA that is reasonably likely to result in Borrower’s incurring any liability that could have a Material Adverse Effect. Borrower is not required to be registered as an “investment company” or a company “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940. Borrower is not engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulations T and U of the Board of Governors of the Federal Reserve System). Borrower has complied in all material respects with all the provisions of the Federal Fair Labor Standards Act.

 

3.14          Shares. Borrower has full power and authority to create a first priority Lien on the Shares and no disability or contractual obligation exists that would prohibit Borrower from pledging the Shares pursuant to this Agreement. To Borrower’s knowledge, there are no subscriptions, warrants, rights of first refusal or other restrictions on transfer relative to, or options exercisable with respect to the Shares. The Shares have been and will be duly authorized and validly issued, and are fully paid and non-assessable. To Borrower’s knowledge, the Shares are not the subject of any present or threatened suit, action, arbitration, administrative or other proceeding, and Borrower knows of no reasonable grounds for the institution of any such proceedings.

 

3.15          Compliance with Anti-Corruption Laws. Borrower has not taken any action that would cause a violation of any anti-corruption law, including but not limited to, the Foreign Corrupt Practices Act, the United Kingdom Bribery Act, and all other applicable anti-corruption laws. Borrower, its employees, agents and representatives have not, directly or indirectly, offered, paid, given, promised or authorized the payment of any money, gift or anything of value to any person acting in an official capacity for any government department, agency or instrumentality, including state-owned or controlled companies or entities, and public international organizations, as well as a political party or official thereof or candidate for political office. None of Borrower’s principals or staff are officers, employees or representatives of governments, government agencies, or government-owned or controlled enterprises.

 

4

 

 

3.16          Survival. The representations and warranties of Borrower as set forth in this Agreement survive the execution and delivery of this Agreement.

 

ARTICLE 4 - CONDITIONS PRECEDENT

 

4.1            Conditions to First Loan. The obligation of each Lender to make its first Loan hereunder is, in addition to the conditions precedent specified in Section 4.2 and in any Supplement, subject to the fulfillment of the following conditions and to the receipt by Lenders of the documents described below, duly executed and in form and substance satisfactory to each Lender and its counsel:

 

(a)             Resolutions. A certified copy of the resolutions of the Board of Directors of Borrower authorizing the execution, delivery and performance by Borrower of the Loan Documents.

 

(b)             Incumbency and Signatures. A certificate of the secretary of Borrower certifying the names of the officer or officers of Borrower authorized to sign the Loan Documents, together with a sample of the true signature of each such officer.

 

(c)             Legal Opinion. The opinion of legal counsel for Borrower as to such matters as Agent may reasonably request, in form and substance satisfactory to Agent.

 

(d)             Charter Documents. Copies of the organizational and charter documents of Borrower (e.g., Articles or Certificate of Incorporation and Bylaws), as amended through the Closing Date, certified by an officer of Borrower as being true, correct and complete.

 

(e)             This Agreement. Counterparts of this Agreement and the initial Supplement, with all schedules completed and attached thereto, and disclosing such information as is acceptable to the Required Lenders.

 

(f)             Financing Statements. Filing copies (or other evidence of filing satisfactory to Agent and its counsel) of such UCC financing statements, collateral assignments, account control agreements, and termination statements, with respect to the Collateral as Agent shall request.

 

(g)             Intellectual Property Security Agreement. An Intellectual Property Security Agreement executed by each Borrower in form and substance satisfactory to Agent.

 

(h)             Lien Searches. UCC lien, judgment, bankruptcy and tax lien searches of Borrower from such jurisdictions or offices as Lender may reasonably request, all as of a date reasonably satisfactory to Agent and its counsel.

 

(i)             Good Standing Certificate. A certificate of status or good standing of Borrower as of a date acceptable to Lender from the jurisdiction of Borrower’s organization and any foreign jurisdictions where Borrower is qualified to do business.

 

(j)             Warrant. A Warrant issued by Borrower to each Lender exercisable for such number, type and class of shares of Borrower’s capital stock, and for an initial exercise price as is specified therein.

 

(k)            Insurance Certificates. Insurance certificates showing Agent as loss payee or additional insured.

 

(l)             Payoff Documentation. A duly executed payoff letter from Western Alliance Bank accompanied by written evidence (including any UCC termination statements) that all Liens in favor of Western Alliance Bank will be terminated or released upon satisfaction of all Indebtedness owing to Western Alliance Bank.

 

(m)            Restricted Account. Evidence satisfactory to Agent that the Restricted Account is open.

 

(n)            Account Control Agreements. Duly executed Account Control Agreements with respect to any Deposit Account, Securities Account, or Commodity Account of Borrower (other than with respect to any Excluded Account).

 

(o)             Other Documents. Such other documents and instruments as Agent or Lenders may reasonably request to effectuate the intents and purposes of this Agreement.

 

5

 

 

4.2            Conditions to All Loans. The obligation of each Lender to make its initial Loan and each subsequent Loan is subject to the following further conditions precedent that:

 

(a)             No Default. No Default or Event of Default has occurred and is continuing or will result from the making of any such Loan, and the representations and warranties of Borrower contained in Article 3 of this Agreement and Part 3 of the Supplement are true and correct in all material respects as of the Borrowing Date of such Loan (other than those representations and warranties expressly referring to a specific date which are true and correct in all material respects as of such date).

 

(b)             No Material Adverse Change. No event has occurred and is continuing that has had or could reasonably be expected to have a Material Adverse Change.

 

(c)             Borrowing Request. Borrower shall have delivered to Agent a Borrowing Request for the Loans.

 

(d)             Note. Borrower shall have delivered an executed Note to each Lender evidencing the Loan made by such Lender, substantially in the form attached to the Supplement as an exhibit.

 

(e)             Supplemental Lien Filings. Borrower shall have executed and delivered such amendments or supplements to this Agreement and additional Security Documents, financing statements and third party waivers as Agent may reasonably request in connection with the proposed Loan, in order to create, protect or perfect or to maintain the perfection of Agent’s Liens on the Collateral.

 

(f)             [Reserved].

 

(g)             Financial Projections. Borrower shall have delivered to Agent Parent’s consolidated business plan and/or financial projections or forecasts as most recently approved by Borrower’s Board of Directors.

 

4.3            Post-Closing Conditions. Borrower shall deliver to Agent the following:

 

(a)            Within ten (10) days of the Closing Date (or such late date as Agent may agree in its sole discretion) a duly executed Account Control Agreement with respect to Borrower’s account(s) maintained at Chase Bank.

 

(b)            Within fifteen (15) days of the Closing Date (or such late date as Agent may agree in its sole discretion) a duly executed Account Control Agreement with respect to any foreign-denominated account(s).

 

ARTICLE 5 - AFFIRMATIVE COVENANTS

 

During the term of this Agreement and until its performance of all Obligations (other than inchoate indemnity obligations), Borrower will:

 

5.1            Notice to Lenders. Promptly give written notice to Agent of:

 

(a)             Any litigation or administrative or regulatory proceeding affecting Borrower where the amount claimed against Borrower is at the Threshold Amount or more, or where the granting of the relief requested could reasonably be expected to have a Material Adverse Effect; or of the acquisition by Borrower of any commercial tort claim, including brief details of such claim and such other information as Agent may reasonably request to enable Agent to better perfect its Lien in such commercial tort claim as Collateral.

 

(b)             Any substantial dispute which may exist between Borrower and any governmental or regulatory authority.

 

(c)            The occurrence of any Default or any Event of Default.

 

(d)             Any change in the location of any of Borrower’s places of business or Collateral at least thirty (30) days in advance of such change, or of the establishment of any new, or the discontinuance of any existing, place of business.

 

(e)             Any dispute or default by Borrower or any other party under any joint venture, partnering, distribution, cross-licensing, strategic alliance, collaborative research or manufacturing, license or similar agreement which could reasonably be expected to have a Material Adverse Effect.

 

(f)             Any other matter which has resulted or could reasonably be expected to result in a Material Adverse Change.

 

(g)            Any Subsidiary Borrower intends to acquire or create.

 

6

 

 

5.2            Financial Statements. Deliver to Agent or cause to be delivered to Agent, in form and detail satisfactory to Agent the following financial and other information, which Borrower warrants shall be accurate and complete in all material respects:

 

(a)             Monthly Financial Statements. As soon as available but no later than thirty (30) days after the end of each month, Parent’s unaudited consolidated balance sheet as of the end of such period, and Parent’s unaudited consolidated income statement and, for each month that is the last month of a fiscal quarter, cash flow statement for such period and for that portion of Parent’s financial reporting year ending with such period (except that the cash flow statement shall cover the entire applicable fiscal quarter), prepared in accordance with GAAP and attested by a responsible financial officer of Parent as being complete and correct in all material respects and fairly presenting Parent’s and each Subsidiaries’ financial condition and the results of Parent’s and each Subsidiaries’ operations as of the date(s) and for the period(s) covered thereby, subject to the absence of footnotes and normal year-end audit adjustments.

 

(b)             Year-End Financial Statements. As soon as available but no later than ninety (90) days after the end of each financial reporting year, a complete copy of Parent’s consolidated audit report, which shall include balance sheet, income statement, statement of changes in equity and statement of cash flows for such year, prepared in accordance with GAAP and certified by WithumSmith + Brown, PC or another independent certified public accountant selected by Parent and reasonably satisfactory to Lender (the Accountant). The Accountant’s certification shall not be qualified or limited due to a restricted or limited examination by the Accountant of any material portion of Parent or any Subsidiary’s records.

 

(c)             Compliance Certificates. Simultaneously with the delivery of each set of financial statements referred to in paragraphs (a) and (b) above, a certificate of the chief financial officer of Borrower (or other executive officer) substantially in the form of Exhibit “C” to the Supplement (a Compliance Certificate) stating, among other things, whether any Default or Event of Default exists on the date of such certificate, and if so, setting forth the details thereof and the action which Borrower is taking or proposes to take with respect thereto.

 

(d)             Government Required Reports. Promptly after sending, issuing, making available, or filing, copies of all reports, proxy statements, and financial statements that Borrower sends or makes available generally to its stockholders, and, not later than five (5) days after actual filing or the date such filing was first due, all registration statements and reports that Borrower files or is required to file with the Securities and Exchange Commission, or any other governmental or regulatory authority having similar authority.

 

(e)             Other Information. Such other financial statements, lists of property and accounts, budgets (as updated), sales projections, forecasts, reports, 409A valuation reports (as updated), operating plans, financial exhibits, and information relating to equity and debt financings consummated after the Closing Date (including post-closing capitalization table(s)), or other information as any Lender may from time to time reasonably request.

 

(f)              Board Packages. In addition to the information described in Section 5.2(e), Borrower will promptly provide Agent with copies of all notices, minutes, consents and other materials, financial or otherwise, which Borrower provides to its Board of Directors (collectively, Board Packages); provided, however, that Borrower need not provide Agent with copies of routine Board actions, such as option and stock grants under Borrower’s equity incentive plan in the normal course of business; and provided, further, however, that such Board Packages may be redacted to the extent that (i) based on the advice of counsel, Borrower’s Board of Directors determines such redaction is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential proprietary information, or for other similar reasons or (ii) such redacted material relates to Agent or any Lender (or Borrower’s strategy regarding the Loans or Agent or any Lender).

 

5.3            [Reserved].

 

5.4            Existence. Except as otherwise expressly permitted under this Agreement, maintain and preserve Borrower’s existence, present form of business, and all rights and privileges necessary in the normal course of its business; and keep all Borrower’s property in good working order and condition, ordinary wear and tear and casualty excepted.

 

5.5            Insurance. Obtain and keep in force insurance in such amounts and types as is usual in the type of business conducted by Borrower, with insurance carriers having a policyholder rating of not less than “A” and financial category rating of Class VII in “Best’s Insurance Guide,” unless otherwise approved by the Required Lenders. Such insurance policies must be in form and substance reasonably satisfactory to the Required Lenders, and shall list Agent as an additional insured or loss payee, as applicable, on endorsement(s) in form reasonably acceptable to Agent. Borrower shall furnish to Agent such endorsements, and upon Agent’s or any Lender’s request, copies of any or all such policies.

 

7

 

 

5.6            Accounting Records. Maintain adequate books, accounts and records, and prepare all financial statements in accordance with GAAP, and in compliance in all material respects with the regulations of any governmental or regulatory authority having jurisdiction over Parent or any Subsidiary or Parent or any Subsidiary’s business; and permit employees or agents of Agent at such reasonable times as Agent may request, at Borrower’s expense (not to exceed, together with the costs of any inspections under Section 5.9(a), Two Thousand Five Hundred Dollars ($2,500) in any 12-month period unless an Event of Default has occurred and is continuing), to inspect Borrower’s properties, and to examine, review and audit, and make copies and memoranda of Borrower’s books, accounts and records.

 

5.7            Compliance with Laws. Comply with all laws (including Environmental Laws), rules, regulations applicable to, and all orders and directives of any governmental or regulatory authority having jurisdiction over, Parent or any Subsidiary or Parent or any Subsidiary’s business, and with all material agreements to which Parent or any Subsidiary is a party, except where the failure to so comply would not have a Material Adverse Effect.

 

5.8            Taxes and Other Liabilities. Pay all of Parent and each Subsidiary’s Indebtedness when due; pay all taxes and other governmental or regulatory assessments before delinquency or before any penalty attaches thereto, except as may be contested in good faith by the appropriate procedures and for which Borrower shall maintain appropriate reserves; and timely file all required tax returns (subject to any applicable extensions).

 

5.9            Special Collateral Covenants.

 

(a)             Maintenance of Collateral; Inspection. Do all things reasonably necessary to maintain, preserve, protect and keep all Collateral in good working order and salable condition, ordinary wear and tear and casualty excepted, deal with the Collateral in all commercially reasonable ways as are considered good practice by owners of like property, and use the Collateral lawfully and, to the extent applicable, only as permitted by Borrower’s insurance policies. Maintain, or cause to be maintained, complete and accurate Records, in all material respects, relating to the Collateral. Upon reasonable prior notice at reasonable times during normal business hours, at Borrower’s expense (not to exceed, together with the costs of any inspections under Section 5.6, Two Thousand Five Hundred Dollars ($2,500) in any 12-month period unless an Event of Default has occurred and is continuing), Borrower hereby authorizes Agent’s officers, employees, representatives and agents to inspect the Collateral and to discuss the Collateral and the Records relating thereto with Borrower’s officers and employees, and, in the case of any Right to Payment, after consultation with, and together with, Borrower, with any Person which is or may be obligated thereon.

 

(b)             Documents of Title. Not sign or authorize the signing of any financing statement or other document naming Borrower as debtor or obligor, or acquiesce or cooperate in the issuance of any bill of lading, warehouse receipt or other document or instrument of title with respect to any Collateral, except those negotiated to Agent, or those naming Agent as secured party, or if solely to create, perfect or maintain a Permitted Lien.

 

(c)             Change in Location or Name. Without at least 30 days’ prior written notice to Agent and Lenders: (a) not relocate any Collateral or Records, its chief executive office, or establish a place of business at a location other than as specified in the Supplement; and (b) not change its name, mailing address, location of Collateral, jurisdiction of incorporation or its legal structure.

 

(d)            [Reserved].

 

(e)             Agreement with Persons in Possession of Collateral. Use its commercially reasonable efforts to obtain and maintain such acknowledgments, consents, waivers and agreements (each a Waiver) from the owner, operator, lienholder, mortgagee, landlord or any Person in possession of tangible Collateral in excess of the Threshold Amount per location as Agent may require, all in form and substance reasonably satisfactory to Agent. In addition, Agent shall have the right to require Borrower to use its commercially reasonable efforts to provide Agent with a Waiver for any Collateral that is located in a jurisdiction that provides for statutory landlord’s Liens and for any location at which the Person in possession of such Collateral in excess of the Threshold Amount has a Lien thereon. Notwithstanding anything to the contrary in this Section 5.9(e), Borrower, Agent and Lenders acknowledge and agree that all material Intellectual Property and Records that are maintained on items of Collateral for which Borrower is unable to provide a Waiver also shall be maintained or backed up in a manner sufficient that Agent shall be able to have access to such Intellectual Property and Records in accordance with the exercise of Agent’s rights hereunder.

 

8

 

 

(f)              Certain Agreements on Rights to Payment. Other than in the ordinary course of business, not make any material discount, credit, rebate or other reduction in the original amount owing on a Right to Payment or accept in satisfaction of a Right to Payment less than the original amount thereof.

 

5.10          Authorization for Automated Clearinghouse Funds Transfer. (i) Authorize each Lender to initiate debit entries to Borrower’s Primary Operating Account, specified in the Supplement hereto, through Automated Clearinghouse (ACH) transfers, in order to satisfy the regularly scheduled payments of principal and interest; (ii) provide each Lender at least thirty (30) days’ notice of any change in Borrower’s Primary Operating Account; and (iii) grant each Lender any additional authorizations necessary to begin ACH debits from a new account which becomes the Primary Operating Account.

 

5.11          Anti-Corruption Laws. Provide true, accurate and complete information, in all material respects, in all product orders, reimbursement requests and other communications relating to Parent, its Subsidiaries and their products.

 

5.12          LTM Product Revenue. Borrower shall achieve LTM Product Revenue, tested monthly as of the last day of each month, of at least the amounts set forth below:

 

Each Month Ending
on or During the
Following Periods:
LTM Product
Revenue
June 30, 2024 – December 31, 2024 [*]
January 31, 2025 – December 31, 2025 [*]
January 31, 2026 and thereafter [*]

 

ARTICLE 6 - NEGATIVE COVENANTS

 

During the term of this Agreement and until the performance of all Obligations (other than inchoate indemnity obligations), Parent and its Subsidiaries will not:

 

6.1            Indebtedness. Be indebted for borrowed money, the deferred purchase price of property, or leases which would be capitalized in accordance with GAAP; or become liable as a surety, guarantor, accommodation party or otherwise for or upon the obligation of any other Person, except for Permitted Indebtedness.

 

6.2            Liens. Create, incur, assume or permit to exist any Lien, or grant any other Person a negative pledge, on any of Borrower’s property, except Permitted Liens and any negative pledge in respect of any asset subject to a Lien permitted by clause (c) of the definition of Permitted Liens. Borrower, Agent and each Lender agree that this covenant is not intended to constitute a lien, deed of trust, equitable mortgage, or security interest of any kind on any of Borrower’s real property, and this Agreement shall not be recorded or recordable. Notwithstanding the foregoing, however, violation of this covenant by Borrower shall constitute an Event of Default.

 

6.3            Dividends. Pay any dividends or purchase, redeem or otherwise acquire or make any other distribution with respect to any of Borrower’s capital stock, except (a) dividends or other distributions solely of capital stock of Borrower, (b) so long as no Event of Default has occurred and is continuing, repurchases of stock from employees or contractors upon termination of employment or services under reverse vesting or similar repurchase plans not to exceed One Hundred Thousand Dollars ($100,000) in any calendar year, (c) the conversion of Borrower’s convertible securities into other securities pursuant to the terms of such convertible securities or otherwise in exchange thereof, and (d) the purchase, redemption or other acquisition of shares of Borrower’s capital stock with the proceeds received from a substantially concurrent issue of new shares of its capital stock.

 

9

 

 

6.4            Fundamental Changes. (a) Liquidate or dissolve (provided that a Subsidiary may liquidate or dissolve into a Borrower or another Subsidiary of Borrower); (b) enter into, or permit any of Borrower’s Subsidiaries to enter into, any Change of Control; or (c) acquire, or permit any of Borrower’s Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person. Notwithstanding anything to the contrary in this Section 6.4, Borrower may enter into a transaction that will constitute a Change of Control so long as: (i) the Person that results from such Change of Control (the Surviving Entity) shall have executed and delivered to Agent and Lenders an agreement in form and substance reasonably satisfactory to Agent and Lenders, containing an assumption by the Surviving Entity of the due and punctual payment and performance of all Obligations and performance and observance of each covenant and condition of Borrower in the Loan Documents; (ii) all such obligations of the Surviving Entity to Lenders shall be guaranteed by any Person that directly or indirectly owns or controls 50% or more of the voting stock of the Surviving Entity; (iii) immediately after giving effect to such Change of Control, no Event of Default or, event which with the lapse of time or giving of notice or both, would result in an Event of Default shall have occurred and be continuing; and (iv) the credit risk to Lenders, in each Lender’s sole discretion, with respect to the Obligations and the Collateral shall not be increased. In determining whether the proposed Change of Control would result in an increased credit risk, Lenders may consider, among other things, changes in Borrower’s management team, employee base, access to equity markets, venture capital support, financial position and/or disposition of intellectual property rights which may reasonably be anticipated as a result of the Change of Control. In addition, (i) a Subsidiary may merge or consolidate into another Subsidiary, (ii) this Section 6.4 shall not apply to any Transfer permitted under Section 6.5 and (iii) Borrower may consolidate or merge with any of Borrower’s Subsidiaries provided that Borrower is the continuing or surviving Person.

 

6.5            Sales of Assets. Sell, transfer, lease, license or otherwise dispose of (a Transfer) any of Borrower’s assets except (i) non-exclusive licenses or similar arrangements of property in the ordinary course of business consistent with industry practice, provided that such licenses neither result in a legal transfer of title of the licensed property nor have the same effect as a sale of such property; (ii) Transfers of worn-out, obsolete or surplus property (each as determined by Borrower in its reasonable judgment); (iii) Transfers of Inventory in the ordinary course of business; (iv) Transfers constituting Permitted Liens; (v) Transfers permitted in Section 6.3, 6.4, 6.6 or 6.7 hereunder; (vi) making of royalty payments in accordance with the terms of the [*] Agreement, the [*] Agreement and the [*] Agreement; and (vii) Transfers of assets (other than Intellectual Property) for fair consideration and in the ordinary course of its business.

 

6.6            Loans/Investments. Make or suffer to exist any loans, guaranties, advances, or investments (Investments), except for Permitted Investments.

 

6.7            Transactions with Related Persons. Directly or indirectly enter into any transaction with or for the benefit of a Related Person on terms more favorable to the Related Person than would have been obtainable in an “arms’ length” dealing, except (a) sales of equity securities by Borrower and incurrence of Subordinated Debt for capital raising purposes, (b) Permitted Investments and Permitted Indebtedness and (c) sales of inventory from Borrower to any Subsidiary pursuant to standard transfer pricing arrangements and in the ordinary course of business.

 

6.8            Other Business. Engage in any material line of business other than the business Borrower conducts as of the Closing Date and any business substantially similar or related or incidental thereto.

 

6.9            Financing Statements and Other Actions. Fail to execute and deliver to Agent all financing statements, notices and other documents (including, without limitation, any filings with the United States Patent and Trademark Office and the United States Copyright Office) from time to time reasonably requested by Agent to maintain a perfected first priority security interest in the Collateral in favor of Agent, subject to Permitted Liens; perform such other acts, and execute and deliver to Agent such additional conveyances, assignments, agreements and instruments, as Agent may at any time reasonably request in connection with the administration and enforcement of this Agreement or Agent’s rights, powers and remedies hereunder.

 

6.10          Compliance. Become required to be registered as an “investment company” or controlled by an “investment company,” within the meaning of the Investment Company Act of 1940, or become principally engaged in, or undertake as one of its important activities, the business of extending credit for the purpose of purchasing or carrying margin stock, or use the proceeds of any Loan for such purpose. Fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur, fail to comply with the Federal Fair Labor Standards Act or violate any law or regulation, which violation could reasonably be expected to have a Material Adverse Effect or a material adverse effect on the Collateral or the priority of Agent’s Lien on the Collateral, or permit any of its Subsidiaries to do any of the foregoing.

 

10

 

 

6.11          Other Deposit and Securities Accounts. Maintain any Deposit Accounts or accounts holding securities owned by Borrower except (i) Deposit Accounts and investment/securities accounts as set forth in the Supplement, and (ii) other Deposit Accounts and securities/investment accounts, in each case, with respect to which Borrower and Agent shall have taken such action as Agent reasonably deems necessary to obtain a perfected first priority security interest therein, subject to Permitted Liens. The provisions of the previous sentence shall not apply to Deposit Accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower’s employees and identified to Agent as such (all such accounts, “Excluded Accounts”).

 

6.12          Prepayment of Indebtedness. Prepay, redeem or otherwise satisfy in any manner prior to the scheduled repayment thereof any Indebtedness (other than the Loans and Indebtedness permitted by Section 6.1 hereof). Notwithstanding the foregoing, Agent and each Lender agrees that the conversion or exchange into Borrower’s equity securities of any Indebtedness (other than the Loans) shall not be prohibited by this Section 6.12.

 

6.13          Repayment of Subordinated Debt. Repay, prepay, redeem or otherwise satisfy in any manner any Subordinated Debt, except in accordance with the terms of any subordination agreement among Borrower, Agent and the holder(s) of such Subordinated Debt. Notwithstanding the foregoing, each Lender agrees that the conversion or exchange into Borrower’s equity securities of any Subordinated Debt and the payment of cash in lieu of fractional shares shall not be prohibited by this Section 6.13.

 

6.14          Subsidiaries.

 

(a)             Acquire or create any Subsidiary, unless such Subsidiary becomes, at Agent’s option, either a co-borrower hereunder or executes and delivers to Agent one or more agreements, in form and substance reasonably satisfactory to Agent, containing a guaranty of the Obligations that is secured by first priority Liens on such Person’s assets, subject to Permitted Liens. For clarity, the parties acknowledge and agree that Agent, upon consultation with the Required Lenders shall have the exclusive right to determine whether any such Person will be made a co-borrower hereunder or a guarantor of the Obligations. Prior to the acquisition or creation of any such Subsidiary, Borrower shall notify Agent and Lenders thereof in writing, which notice shall contain the jurisdiction of such Person’s formation and include a description of such Person’s fully diluted capitalization and Borrower’s purpose for its acquisition or creation of such Subsidiary. Notwithstanding the foregoing, no foreign Subsidiary which accounts for less than five percent (5.00%) of Parent’s consolidated Revenue and assets individually or ten percent (10.00%) of Parent’s consolidated Revenue and assets in aggregate shall be required to become a co-Borrower hereunder or a guarantor of the Obligations.

 

(b)             Sell, transfer, encumber or otherwise dispose of Borrower’s ownership interest in any Subsidiary other than Permitted Liens and Transfers permitted under Section 6.5.

 

(c)             Cause or permit a Subsidiary to do any of the following: (i) grant Liens on such Subsidiary’s assets, except for Liens that would constitute Permitted Liens if incurred by Borrower and Liens on any property held or acquired by such Subsidiary in the ordinary course of its business securing Indebtedness incurred or assumed for the purpose of financing all or any part of the cost of acquiring such property; provided, that such Lien attaches solely to the property acquired with such Indebtedness and that the principal amount of such Indebtedness does not exceed one hundred percent (100%) of the cost of such property; and (ii) issue any additional Shares, except to Borrower or a wholly owned Subsidiary of Borrower.

 

6.15          Leases. Create, incur, assume, or suffer to exist any obligation as lessee for the rental or hire of any personal property (“Personal Property Leases”), except for Personal Property Leases of Equipment in the ordinary course of business that do not in the aggregate require Borrower to make payments (including taxes, insurance, maintenance and similar expenses which Borrower is required to pay under the terms of any such lease) in any calendar year in excess of One Hundred Thousand Dollars ($100,000) in aggregate amount (or such greater amount as Agent may agree in advance in writing). For the avoidance of doubt, this Section 6.15 will not be applicable to Indebtedness otherwise permitted under clause (f) of the definition of Permitted Indebtedness.

 

6.16          Anti-Corruption Laws.

 

(a)             Take any action that would cause a violation of any anti-corruption law, including but not limited to, the Foreign Corrupt Practices Act, the United Kingdom Bribery Act, and all other applicable anti-corruption laws.

 

11

 

 

(b)             Directly or indirectly, offer, pay, give, promise or authorize the payment of any money, gift, or anything of value to any person acting in an official capacity for any government department, agency, or instrumentality, including state-owned or controlled companies or entities, and public international organizations, as well as a political party or official thereof or candidates for political office, except in compliance with applicable law.

 

ARTICLE 7 - EVENTS OF DEFAULT

 

7.1            Events of Default; Acceleration. Upon the occurrence and during the continuation of any Event of Default, the obligation of each Lender to make any additional Loan shall be suspended. The occurrence and continuation of any of the following (each, an Event of Default) shall at the option of Agent, at the direction of the Required Lenders (1) make all sums of Basic Interest and principal, as well as any other Obligations and amounts owing under any Loan Documents, immediately due and payable without notice of default, presentment or demand for payment, protest or notice of nonpayment or dishonor or any other notices or demands, and (2) give Agent the right to exercise any other right or remedy provided by contract or applicable law:

 

(a)             Borrower shall fail to pay any principal or interest under this Agreement or any Note, or fail to pay any fees or other charges when due under any Loan Document, and such failure continues for three (3) Business Days or more after the same first becomes due; or an Event of Default as defined in any other Loan Document shall have occurred.

 

(b)             Any representation or warranty made, or financial statement, certificate or other document provided, by Borrower under any Loan Document shall prove to have been false or misleading in any material respect when made or deemed made herein.

 

(c)             If there occurs any circumstance or circumstances that has a Material Adverse Effect.

 

(d)             (i) Borrower shall fail to pay its debts generally as they become due; or (ii) Borrower shall commence any Insolvency Proceeding with respect to itself, an involuntary Insolvency Proceeding shall be filed against Borrower, or a custodian, receiver, trustee, assignee for the benefit of creditors, or other similar official, shall be appointed to take possession, custody or control of the properties of Borrower, and such involuntary Insolvency Proceeding, petition or appointment is acquiesced to by Borrower or is not dismissed within forty five (45) days; or (iii) the dissolution, winding up, or termination of the business or cessation of operations of Borrower (including any transaction or series of related transactions deemed to be a liquidation, dissolution or winding up of Borrower pursuant to the provisions of Borrower’s charter documents); or (iv) Borrower shall take any corporate action for the purpose of effecting, approving, or consenting to any of the foregoing.

 

(e)             Borrower shall be and continue in default beyond any applicable period of grace or cure under any other agreement involving the borrowing of money, the purchase of property, the advance of credit or any other monetary liability of any kind to any Lender or to any Person in an amount in excess of the Threshold Amount.

 

(f)             Any governmental or regulatory authority shall take any judicial or administrative action, or any defined benefit pension plan maintained by Borrower shall have any unfunded liabilities, any of which, in the reasonable judgment of Agent and each Lender, could reasonably be expected to have a Material Adverse Effect.

 

(g)            Any sale, transfer or other disposition of all or a substantial or material part of the assets of Borrower, including without limitation to any trust or similar entity, shall occur except as permitted under Section 6.5.

 

(h)            Any judgment(s) singly or in the aggregate in excess of the Threshold Amount shall be entered against Borrower which remain unsatisfied, unvacated or unstayed pending appeal for fifteen (15) or more days after entry thereof (to the extent not covered by independent third-party insurance as to which the insurer does not dispute coverage).

 

(i)             Borrower shall fail to perform or observe any covenant contained in Article 6 of this Agreement.

 

(j)             Borrower shall fail to perform or observe any covenant contained in Article 5 or elsewhere in this Agreement or any other Loan Document (other than a covenant which is dealt with specifically elsewhere in this Article 7) and, if capable of being cured, the breach of such covenant is not cured within fifteen (15) days after the sooner to occur of Borrower’s receipt of notice of such breach from Agent or the date on which such breach first becomes known to any officer of Borrower (the “Notice Date”); provided, however that if such breach is not capable of being cured within such 15-day period and Borrower timely notifies Agent and each Lender of such fact and Borrower diligently pursues such cure, then the cure period shall be extended to the date requested in Borrower’s notice but in no event more than thirty (30) days from the Notice Date.

 

12

 

 

(k)            Borrower shall fail to perform any requirement of Section 4.3 hereof.

 

7.2            Remedies upon Default. Upon the occurrence and during the continuance of an Event of Default, Agent, at the direction of the Required Lenders, shall be entitled to exercise any or all of the rights and remedies available to a secured party under the UCC or any other applicable law, and exercise any or all of its rights and remedies provided for in this Agreement and in any other Loan Document. The obligations of Borrower under this Agreement shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any Obligations is rescinded or must otherwise be returned by Agent or any Lender upon, on account of, or in connection with, the insolvency, bankruptcy or reorganization of Borrower or otherwise, all as though such payment had not been made.

 

7.3            Sale of Collateral. Upon the occurrence and during the continuance of an Event of Default, Agent, at the direction of the Required Lenders, may sell all or any part of the Collateral, at public or private sales, to itself, a wholesaler, retailer or investor, for cash, upon credit or for future delivery, and at such price or prices as Agent or the Required Lenders may deem commercially reasonable. To the extent permitted by law, Borrower hereby specifically waives all rights of redemption and any rights of stay or appraisal which it has or may have under any applicable law in effect from time to time. Any such public or private sales shall be held at such times and at such place(s) as Agent, at the direction of the Required Lenders, may determine. In case of the sale of all or any part of the Collateral on credit or for future delivery, the Collateral so sold may be retained by Agent until the selling price is paid by the purchaser, but neither Agent nor any Lender shall incur any liability in case of the failure of such purchaser to pay for the Collateral and, in case of any such failure, such Collateral may be resold. Agent may, at the direction of the Required Lenders, instead of exercising its power of sale, proceed to enforce its security interest in the Collateral by seeking a judgment or decree of a court of competent jurisdiction. Without limiting the generality of the foregoing, if an Event of Default is in existence,

 

(1)             Subject to the rights of any third parties, Agent may license, or sublicense, whether general, special or otherwise, and whether on an exclusive or non-exclusive basis, any Copyrights, Patents or Trademarks included in the Collateral throughout the world for such term or terms, on such conditions and in such manner as the Required Lenders shall in their sole discretion determine;

 

(2)             Agent, at the direction of the Required Lenders, may (without assuming any obligations or liability thereunder), at any time and from time to time, enforce (and shall have the exclusive right to enforce) against any licensee or sublicensee all rights and remedies of Borrower in, to and under any Copyright Licenses, Patent Licenses or Trademark Licenses and take or refrain from taking any action under any thereof, and Borrower hereby releases Agent and each Lender from, and agrees to hold Agent and each Lender free and harmless from and against any claims arising out of, any lawful action so taken or omitted to be taken with respect thereto other than claims arising out of Agent’s or any Lender’s gross negligence or willful misconduct; and

 

(3)             Upon request by Agent, at the direction of the Required Lenders, Borrower will execute and deliver to Agent a power of attorney, in form and substance reasonably satisfactory to Agent for the implementation of any lease, assignment, license, sublicense, grant of option, sale or other disposition of a Copyright, Patent or Trademark. In the event of any such disposition pursuant to this clause 3, Borrower shall supply its know-how and expertise relating to the products or services made or rendered in connection with Patents, the manufacture and sale of the products bearing Trademarks, and its customer lists and other records relating to such Copyrights, Patents or Trademarks and to the distribution of said products, to Agent.

 

(4)             If, at any time when Agent, at the direction of the Required Lenders, shall determine to exercise the right to sell the whole or any part of the Shares hereunder, such Shares or the part thereof to be sold shall not, for any reason whatsoever, be effectively registered under the Securities Act (or any similar statute), then Agent may, in its discretion (subject only to applicable requirements of law), sell such Shares or part thereof by private sale in such manner and under such circumstances as Agent, at the direction of the Required Lenders may deem necessary or advisable, but subject to the other requirements of this Article 7, and shall not be required to effect such registration or to cause the same to be effected. Without limiting the generality of the foregoing, in any such event, Agent may, at the direction of the Required Lenders in their sole discretion (i) in accordance with applicable securities laws proceed to make such private sale notwithstanding that a registration statement for the purpose of registering such Shares or part thereof could be or shall have been filed under the Securities Act (or similar statute), (ii) approach and negotiate with a single possible purchaser to effect such sale, and (iii) restrict such sale to a purchaser who is an accredited investor under the Securities Act and who will represent and agree that such purchaser is purchasing for its own account, for investment and not with a view to the distribution or sale of such Shares or any part thereof. In addition to a private sale as provided above in this Article 7, if any of the Shares shall not be freely distributable to the public without registration under the Securities Act (or similar statute) at the time of any proposed sale pursuant to this Article 7, then Agent shall not be required to effect such registration or cause the same to be effected but, in its discretion (subject only to applicable requirements of law), may require that any sale hereunder (including a sale at auction) be conducted subject to restrictions:

 

(A)            as to the financial sophistication and ability of any Person permitted to bid or purchase at any such sale;

 

13

 

 

(B)            as to the content of legends to be placed upon any certificates representing the Shares sold in such sale, including restrictions on future transfer thereof;

 

(C)            as to the representations required to be made by each Person bidding or purchasing at such sale relating to such Person’s access to financial information about Borrower or any of its Subsidiaries and such Person’s intentions as to the holding of the Shares so sold for investment for its own account and not with a view to the distribution thereof; and

 

(D)            as to such other matters as Agent may, in its discretion, deem necessary or appropriate in order that such sale (notwithstanding any failure so to register) may be effected in compliance with the Bankruptcy Code and other laws affecting the enforcement of creditors’ rights and the Securities Act and all applicable state securities laws.

 

(5)             Borrower recognizes that Agent may be unable to effect a public sale of any or all the Shares and may be compelled to resort to one or more private sales thereof in accordance with clause (4) above. Borrower also acknowledges that any such private sale may result in prices and other terms less favorable to the seller than if such sale were a public sale and, notwithstanding such circumstances, agrees that any such private sale shall not be deemed to have been made in a commercially unreasonable manner solely by virtue of such sale being private. Agent shall be under no obligation to delay a sale of any of the Shares for the period of time necessary to permit the applicable Subsidiary to register such securities for public sale under the Securities Act, or under applicable state securities laws, even if Borrower and/or the Subsidiary would agree to do so.

 

7.4            Borrower’s Obligations upon Default. Upon the request of Agent, at the direction of Lenders, after the occurrence and during the continuance of an Event of Default, Borrower will:

 

(a)             Assemble and make available to Agent the Collateral at such place(s) as Agent shall reasonably designate, segregating all Collateral so that each item is capable of identification; and

 

(b)             Subject to the rights of any lessor, permit Agent, by Agent’s officers, employees, agents and representatives, to enter any premises where any Collateral is located, to take possession of the Collateral, to complete the processing, manufacture or repair of any Collateral, and to remove the Collateral, or to conduct any public or private sale of the Collateral, all without any liability of Agent or any Lender for rent or other compensation for the use of Borrower’s premises.

 

ARTICLE 8 - SPECIAL COLLATERAL PROVISIONS

 

8.1            Compromise and Collection. Borrower and Agent recognize that setoffs, counterclaims, defenses and other claims may be asserted by obligors with respect to certain of the Rights to Payment; that certain of the Rights to Payment may be or become uncollectible in whole or in part; and that the expense and probability of success of litigating a disputed Right to Payment may exceed the amount that reasonably may be expected to be recovered with respect to such Right to Payment. Borrower hereby authorizes Agent, after and during the continuance of an Event of Default, to compromise with the obligor, accept in full payment of any Right to Payment such amount as Agent shall negotiate with the obligor, or abandon any Right to Payment. Any such action by Agent shall be considered commercially reasonable so long as the Required Lenders have made the determination in good faith based on information known to them at the time Agent takes any such action.

 

14

 

 

8.2            Performance of Borrower’s Obligations. Without having any obligation to do so, upon reasonable prior notice to Borrower, Agent may, at the direction of the Required Lenders, perform or pay any obligation which Borrower has agreed to perform or pay under this Agreement, including, without limitation, the payment or discharge of taxes or Liens levied or placed on or threatened against the Collateral. In so performing or paying, Agent and the Required Lenders shall determine the action to be taken and the amount necessary to discharge such obligations. Borrower shall reimburse Agent on demand for any amounts paid by Agent and each Lender pursuant to this Section, which amounts shall constitute Obligations secured by the Collateral and shall bear interest from the date of demand at the Default Rate.

 

8.3            Power of Attorney. For the purpose of protecting and preserving the Collateral and Agent’s rights under this Agreement, Borrower hereby irrevocably appoints Agent, with full power of substitution, as its attorney-in-fact with full power and authority, after the occurrence and during the continuance of an Event of Default, to do any act which Borrower is obligated to do hereunder; to exercise such rights with respect to the Collateral as Borrower might exercise; to use such Inventory, Equipment, Fixtures or other property as Borrower might use; to enter Borrower’s premises; to give notice of Agent’s security interest in, and to collect the Collateral; and before or after Default, to execute and file in Borrower’s name any financing statements, amendments and continuation statements, Account Control Agreements or other Security Documents necessary or desirable to create, maintain, perfect or continue the perfection of Agent’s security interests in the Collateral. Borrower hereby ratifies all that Agent shall lawfully do or cause to be done by virtue of this appointment.

 

8.4            Authorization for Agent to Take Certain Action. The power of attorney created in Section 8.3 is a power coupled with an interest and shall be irrevocable. The powers conferred on Agent hereunder are solely to protect its interests in the Collateral and shall not impose any duty upon Agent to exercise such powers. Agent shall be accountable only for amounts that it actually receives as a result of the exercise of such powers and in no event shall Agent or any of its directors, officers, employees, agents or representatives be responsible to Borrower for any act or failure to act, except for gross negligence or willful misconduct. After the occurrence and during the continuance of an Event of Default, Agent may exercise this power of attorney without notice to or assent of Borrower, in the name of Borrower, or in Agent’s own name, from time to time in Agent’s sole discretion and at Borrower’s expense. To further carry out the terms of this Agreement, after the occurrence and during the continuance of an Event of Default, Agent may, at the direction of the Required Lenders:

 

(a)             Execute any statements or documents or take possession of, and endorse and collect and receive delivery or payment of, any checks, drafts, notes, acceptances or other instruments and documents constituting Collateral, or constituting the payment of amounts due and to become due or any performance to be rendered with respect to the Collateral.

 

(b)             Sign and endorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts; drafts, certificates and statements under any commercial or standby letter of credit relating to Collateral; assignments, verifications and notices in connection with Accounts; or any other documents relating to the Collateral, including without limitation the Records.

 

(c)             Use or operate Collateral or any other property of Borrower for the purpose of preserving or liquidating Collateral.

 

(d)             File any claim or take any other action or proceeding in any court of law or equity or as otherwise deemed appropriate by Agent for the purpose of collecting any and all monies due or securing any performance to be rendered with respect to the Collateral.

 

(e)             Commence, prosecute or defend any suits, actions or proceedings or as otherwise deemed appropriate by Agent for the purpose of protecting or collecting the Collateral. In furtherance of this right, upon the occurrence and during the continuance of an Event of Default, Agent may apply for the appointment of a receiver or similar official to operate Borrower’s business.

 

(f)             Prepare, adjust, execute, deliver and receive payment under insurance claims, and collect and receive payment of and endorse any instrument in payment of loss or returned premiums or any other insurance refund or return, and apply such amounts at Agent’s sole discretion, toward repayment of the Obligations or replacement of the Collateral.

 

15

 

 

8.5            Application of Proceeds. Any Proceeds and other monies or property received by Agent pursuant to the terms of this Agreement or any Loan Document may be applied as follows:

 

(a)             First, to Agent, the aggregate amount of all reasonable out of pocket costs, expenses, indemnities and other amounts required to be reimbursed to Agent, in its capacity as such, until paid in full;

 

(b)             Second, to Agent, for the ratable benefit of Lenders (in accordance with the portion funded by each Lender), the aggregate amount of all Obligations arising on account of payments made by Agent in accordance with Section 8.2, until repaid in full;

 

(c)            Third, to Lenders, ratably in accordance with principal amount of the Loans held by each Lender, an amount equal to the aggregate reasonable out of pocket costs, expenses, indemnities or other amounts then required to be reimbursed to Lenders, until paid in full;

 

(d)             Fourth, to Lenders, ratably in accordance with aggregate amount of any fees, premiums or similar payments due to each Lender in respect of the Loans held by such Lender, an amount equal to the aggregate fees, premiums or other similar such payments due to such Lender in respect of the Loans, until paid in full;

 

(e)             Fifth, to Lenders, ratably in accordance with accrued and unpaid interest in respect of the Loans and the other Obligations due to each Lender, an amount equal to the aggregate accrued and unpaid interest on the Loans and other Obligations then due, until paid in full;

 

(f)             Sixth, to Lenders, ratably in accordance outstanding principal due to each Lender in respect of the Loans, an amount equal to the aggregate principal outstanding in respect of the Loans then due, until paid in full;

 

(g)             Seventh, to Agent and each Lender, ratably in accordance with the any other Obligations due to such Lender, an amount equal to all other Obligations due and payable to Agent and each Lender, until paid in full; and

 

(h)             Last, the balance, if any, to Borrower or as otherwise required by applicable law.

 

8.6            Deficiency. If the Proceeds of any disposition of the Collateral are insufficient to cover all costs and expenses of such sale and the payment in full of all the Obligations, plus all other sums required to be expended or distributed by Agent to Lenders, then Borrower shall be liable for any such deficiency.

 

8.7            Agent Transfer. Upon the transfer of all or any part of the Obligations, Agent may transfer all or part of the Collateral and shall be fully discharged thereafter from all liability and responsibility with respect to such Collateral so transferred, and the transferee shall be vested with all the rights and powers of Agent hereunder with respect to such Collateral so transferred, but with respect to any Collateral not so transferred, Agent shall retain all rights and powers hereby given.

 

8.8            Agent’s Duties.

 

(a)            Agent shall use reasonable care in the custody and preservation of any Collateral in its possession. Without limitation on other conduct which may be considered the exercise of reasonable care, Agent shall be deemed to have exercised reasonable care in the custody and preservation of such Collateral if such Collateral is accorded treatment substantially equal to that which Agent accords its own property, it being understood that Agent shall not have any responsibility for ascertaining or taking action with respect to calls, conversions, exchanges, maturities, declining value, tenders or other matters relative to any Collateral, regardless of whether Agent has or is deemed to have knowledge of such matters; or taking any necessary steps to preserve any rights against any Person with respect to any Collateral. Under no circumstances shall Agent be responsible for any injury or loss to the Collateral, or any part thereof, arising from any cause beyond the reasonable control of Agent.

 

(b)             Agent may at any time deliver the Collateral or any part thereof to Borrower and the receipt of Borrower shall be a complete and full acquittance for the Collateral so delivered, and Agent shall thereafter be discharged from any liability or responsibility therefor.

 

(c)             Neither Agent, nor any of its directors, officers, employees, agents, attorneys or any other person affiliated with or representing Agent shall be liable for any claims, demands, losses or damages, of any kind whatsoever, made, claimed, incurred or suffered by Borrower or any other party through the ordinary negligence of Agent, or any of its directors, officers, employees, agents, attorneys or any other person affiliated with or representing Agent.

 

16

 

 

8.9            Termination of Security Interests and Loan Documents. Upon the payment in full of the Obligations (other than inchoate indemnity obligations) and satisfaction of all Borrower’s obligations under this Agreement and the other Loan Documents, and if Lenders have no further obligations under their Commitment, the security interest granted hereby shall terminate, all rights to the Collateral shall revert to Borrower and this Agreement and the other Loan Documents shall terminate; provided that (i) those obligations, liabilities, covenants and terms that are expressly specified herein and in any other Loan Document as surviving that respective agreement’s termination, including without limitation, Borrower’s indemnity obligations set forth in this Agreement, shall continue to survive notwithstanding anything to the contrary set forth herein, and (ii) nothing set forth herein shall affect or be deemed to affect those obligations, liabilities, covenants and terms set forth in any warrant instrument issued to a Lender’s parent company or set forth in any other equity securities or convertible debt securities of Borrower acquired by any Lender in connection with this Agreement. Upon any such termination, Agent shall return all Collateral in its possession or control to Borrower and, at Borrower’s expense, execute and deliver to Borrower such documents as Borrower shall reasonably request to evidence such termination. In connection therewith, Borrower agrees to provide each Lender with such information as may be reasonably requested by such Lender as to whether the securities issuable upon the exercise of any Warrant issued in connection with this Agreement constitute “qualified small business stock” for purposes of Section 1202(c) of the Internal Revenue Code and Section 18152.5 of the California Revenue and Taxation Code.

 

ARTICLE 9 - GENERAL PROVISIONS

 

9.1            Notices. Any notice given by any party under any Loan Document shall be in writing and personally delivered, sent by overnight courier, or United States mail, postage prepaid, or sent by facsimile or electronic mail, or other authenticated message, charges prepaid, to the other party’s or parties’ addresses shown on the Supplement. Each party may change the address, facsimile number or email address to which notices, requests and other communications are to be sent by giving written notice of such change to each other party. Notice given by hand delivery shall be deemed received on the date delivered; if sent by overnight courier, on the next Business Day after delivery to the courier service; if by first class mail, on the third Business Day after deposit in the U.S. Mail; and if by facsimile or electronic mail, on the date of transmission.

 

9.2            Binding Effect. The Loan Documents shall be binding upon and inure to the benefit of Borrower, Lenders, Agent and their respective successors and assigns; provided, however, that Borrower may not assign or transfer Borrower’s rights or obligations under any Loan Document. Each Lender reserves the right, with the written consent of the Required Lenders, to sell, assign, transfer, negotiate or grant participations in all or any part of, or any interest in, such Lender’s rights and obligations under the Loan Documents provided that, so long as no Event of Default has occurred and is continuing, no Lender shall assign any of such rights or obligations to any competitor of Borrower. Without limiting the foregoing, any Lender may sell, assign, transfer, negotiate or grant participations in all or any part of, or any interest in, such Lender’s rights and obligations under the Loan Documents to any Affiliate of such Lender. In connection with any of the foregoing, Lenders and Agent may disclose all documents and information which Lenders and Agent now or hereafter may have relating to the Loans, Borrower, or its business, provided that any Person who receives such information shall have agreed in writing in advance to maintain the confidentiality of such information on terms no less favorable to Borrower than are set forth in Section 9.13 hereof.

 

9.3            No Waiver. Any waiver, consent or approval by Agent and the Required Lenders of any Event of Default or breach of any provision, condition, or covenant of any Loan Document must be in writing and shall be effective only to the extent set forth in writing and signed by Agent and the Required Lenders. No waiver of any breach or default shall be deemed a waiver of any later breach or default of the same or any other provision of any Loan Document. No failure or delay on the part of Agent or any Lender in exercising any power, right, or privilege under any Loan Document shall operate as a waiver thereof, and no single or partial exercise of any such power, right, or privilege shall preclude any further exercise thereof or the exercise of any other power, right or privilege. Agent and the Required Lenders have the right, at their sole option, to continue to accept interest and/or principal payments due under the Loan Documents after default, and such acceptance shall not constitute a waiver of said default or an extension of the maturity of any Loan unless the Required Lenders agree otherwise in writing.

 

9.4            Rights Cumulative. All rights and remedies existing under the Loan Documents are cumulative to, and not exclusive of, any other rights or remedies available under contract or applicable law.

 

17

 

 

9.5            Unenforceable Provisions. Any provision of any Loan Document executed by Borrower which is prohibited or unenforceable in any jurisdiction, shall be so only as to such jurisdiction and only to the extent of such prohibition or unenforceability, but all the remaining provisions of any such Loan Document shall remain valid and enforceable.

 

9.6            Accounting Terms. Except as otherwise provided in this Agreement, accounting terms and financial covenants and information shall be determined and prepared in accordance with GAAP.

 

9.7            Indemnification; Exculpation. Borrower shall pay and protect, defend and indemnify each Lender, Agent and each Lender’s and Agent’s employees, officers, directors, shareholders, affiliates, correspondents, agents and representatives (other than Lender, collectively “Agents”) against, and hold each Lender, Agent and each of such Agents harmless from, all claims, actions, proceedings, liabilities, damages, losses, expenses (including, without limitation, attorneys’ fees and costs) and other amounts incurred by each Lender, Agent and each of such Agents, arising from (i) the matters contemplated by this Agreement or any other Loan Documents, (ii) any dispute between Borrower and a third party, or (iii) any contention that Borrower has failed to comply with any law, rule, regulation, order or directive applicable to Borrower’s business; provided, however, that this indemnification shall not apply to any of the foregoing to the extent incurred as the result of any Lender’s, Agent’s or any of such Agents’ gross negligence or willful misconduct. This indemnification shall survive the payment and satisfaction of all of Borrower’s Obligations to Lenders.

 

9.8            Reimbursement. Borrower shall reimburse each Lender and Agent for all reasonable out of pocket costs and expenses, including without limitation reasonable attorneys’ fees and disbursements expended or incurred by each Lender and Agent in any arbitration, mediation, judicial reference, legal action or otherwise in connection with (a) the preparation and negotiation of the Loan Documents, (b) the amendment and enforcement of the Loan Documents, including without limitation during any workout, attempted workout, and/or in connection with the rendering of legal advice as to each Lender’s and Agent’s rights, remedies and obligations under the Loan Documents, (c) collecting any sum which becomes due to each Lender under any Loan Document, (d) any proceeding for declaratory relief, any counterclaim to any proceeding, or any appeal, or (e) the protection, preservation or enforcement of any rights of Lenders or Agent under the Loan Documents. For the purposes of this section, attorneys’ fees shall include, without limitation, fees incurred in connection with the following: (1) contempt proceedings; (2) discovery; (3) any motion, proceeding or other activity of any kind in connection with an Insolvency Proceeding; (4) garnishment, levy, and debtor and third party examinations; and (5) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. All of the foregoing costs and expenses shall be payable upon demand by any Lender or Agent, and if not paid within forty-five (45) days of presentation of invoices shall bear interest at the Default Rate.

 

9.9            Execution in Counterparts; Electronic Signatures. This Agreement and the other Loan Documents may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. This Agreement and each of the other Loan Documents may be executed by electronic signatures. Borrower, Agent and Lenders expressly agree to conduct the transactions contemplated by this Agreement and the other Loan Documents by electronic means (including, without limitation, with respect to the execution, delivery, storage and transfer of this Agreement and each of the other Loan Documents by electronic means and to the enforceability of electronic Loan Documents). Delivery of an executed signature page to this Agreement and each of the other Loan Documents by facsimile or other electronic mail transmission (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) shall be effective as delivery of a manually executed counterpart hereof and thereof, as applicable. The words “execution,” “signed,” “signature” and words of like import herein shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity and enforceability as a manually executed signature or the use of a paper-based recordkeeping systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act.

 

18

 

 

9.10          Entire Agreement. No amendment, modification, termination or waiver of any provision of this Agreement or any other Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower or any of its Subsidiaries therefrom, shall in any event be effective unless the same shall be in writing and signed by Borrower, Agent and the Required Lenders provided that:

 

(a)             no such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender’s Commitment shall be effective as to such Lender without such Lender’s written consent;

 

(b)             no such amendment, waiver or modification that would affect the rights and duties of Agent shall be effective without Agent’s written consent;

 

(c)             no such amendment, waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Loan (B) postpone the date fixed for, or waive, any payment of principal of any Loan or of interest on any Loan (other than default interest) or any fees provided for hereunder (other than late charges or for any termination of any commitment); (C) change the definition of the term “Required Lenders” or the percentage of Lenders which shall be required for the Lenders to take any action hereunder; (D) release all or substantially all of any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder); (E) amend, waive or otherwise modify this Section 9.10 or the definitions of the terms used in this Section 9.10 insofar as the definitions affect the substance of this Section 9.10; (F) consent to the assignment, delegation or other transfer by Borrower of any of its rights and obligations under any Loan Document or release Borrower of its payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; (G) amend any of the provisions that provide for Lenders to receive their pro rata portion of any fees, payments, setoffs or proceeds of Collateral hereunder; or (H) subordinate the Liens granted in favor of Agent securing the Obligations.

 

(d)            The Loan Documents are intended by the parties as the final expression of their agreement and therefore contain the entire agreement between the parties and supersede all prior understandings or agreements concerning the subject matter hereof.

 

9.11          Governing Law and Jurisdiction.

 

(a)            THIS AGREEMENT AND THE LOAN DOCUMENTS SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CALIFORNIA.

 

(b)            ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT MAY BE BROUGHT IN THE COURTS OF THE STATE OF CALIFORNIA OR OF THE UNITED STATES FOR THE NORTHERN DISTRICT OF CALIFORNIA, AND BY EXECUTION AND DELIVERY OF THIS AGREEMENT, EACH OF BORROWER, AGENT AND EACH LENDER CONSENTS, FOR ITSELF AND IN RESPECT OF ITS PROPERTY, TO THE NON-EXCLUSIVE JURISDICTION OF THOSE COURTS. EACH OF BORROWER, AGENT AND EACH LENDER IRREVOCABLY WAIVES ANY OBJECTION, INCLUDING ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OF FORUM NON CONVENIENS, WHICH IT MAY NOW OR HEREAFTER HAVE TO THE BRINGING OF ANY ACTION OR PROCEEDING IN SUCH JURISDICTION IN RESPECT OF THIS AGREEMENT OR ANY DOCUMENT RELATED HERETO. BORROWER, AGENT AND EACH LENDER EACH WAIVE PERSONAL SERVICE OF ANY SUMMONS, COMPLAINT OR OTHER PROCESS, WHICH MAY BE MADE BY ANY OTHER MEANS PERMITTED BY CALIFORNIA LAW.

 

9.12          Waiver of Jury Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW, BORROWER, AGENT AND EACH LENDER EACH WAIVES ITS RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF OR RELATED TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, IN ANY ACTION, PROCEEDING OR OTHER LITIGATION OF ANY TYPE BROUGHT BY ANY OF THE PARTIES AGAINST ANY OTHER PARTY OR ANY PARTICIPANT OR ASSIGNEE, WHETHER WITH RESPECT TO CONTRACT CLAIMS, TORT CLAIMS, OR OTHERWISE. BORROWER, AGENT AND EACH LENDER EACH AGREES THAT ANY SUCH CLAIM OR CAUSE OF ACTION SHALL BE TRIED BY A COURT TRIAL WITHOUT A JURY. WITHOUT LIMITING THE FOREGOING, THE PARTIES FURTHER AGREE THAT THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY IS WAIVED BY OPERATION OF THIS SECTION AS TO ANY ACTION, COUNTERCLAIM OR OTHER PROCEEDING WHICH SEEMS, IN WHOLE OR IN PART, TO CHALLENGE THE VALIDITY OR ENFORCEABILITY OF THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS OR ANY PROVISION HEREOF OR THEREOF. THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS.

 

19

 

 

9.13          Confidentiality. Agent and each Lender agrees to hold in confidence all confidential information that it receives from Borrower pursuant to the Loan Documents, except for disclosure as shall be reasonably required: (a) to legal counsel and accountants for Agent and each Lender; (b) to other professional advisors to Agent and each Lender; (c) to regulatory officials having jurisdiction over Lender to the extent required by law; (d) to Agent’s and each Lender’s investors and prospective investors (subject to the same confidentiality obligation set forth herein), and in Agent’s and each Lender’s SEC filings as required by law; (e) as required by law or legal process or in connection with any legal proceeding to which Agent, any Lender and Borrower are adverse parties; (f) in connection with a disposition or proposed disposition of any or all of Agent’s and any Lender’s rights hereunder to any assignee or participant (subject to the same confidentiality obligation set forth herein); (g) to Agent’s and each Lender’s subsidiaries or Affiliates in connection with their business with Borrower (subject to the same confidentiality obligation set forth herein); (h) as required by valid order of a court of competent jurisdiction, administrative agency or governmental body, or by any applicable law, rule, regulation, subpoena, or any other administrative or legal process, or by applicable regulatory or professional standards, including in connection with any judicial or other proceeding involving Agent or any Lender relating to this Agreement and the transactions contemplated hereby; and (i) as required in connection with Agent’s and any Lender’s examination or audit. For purposes of this section, Agent, each Lender and Borrower agree that “confidential information” shall mean any information regarding or relating to Borrower other than: (i) information which is or becomes generally available to the public other than as result of a disclosure by Agent or any Lender in violation of this section, (ii) information which becomes available to Agent or any Lender from any other source (other than Borrower) which neither Agent nor the relevant Lender knows is bound by a confidentiality agreement with respect to the information made available, and (iii) information that Agent or such Lender knows on a non-confidential basis prior to Borrower disclosing it to Agent or such Lender. In addition, Borrower agrees that Agent and each Lender may use Borrower’s name, logo and/or trademark in connection with certain promotional materials that Agent and any Lender may disseminate to the public, including, but are not limited to, brochures, internet website, press releases and any other materials relating to the fact that Agent and each Lender has a financing relationship with Borrower.

 

ARTICLE 10 - AGENCY.

 

10.1          Appointment. Each Lender hereby irrevocably appoints Avenue Capital Management II, L.P. to act on its behalf as the administrative agent hereunder and under the other Loan Documents and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.

 

10.2          Indemnity. Each Lender agrees to indemnify the Agent in its capacity as such (to the extent not reimbursed by Borrowers and without limiting the obligation of Borrowers to do so), according to its respective Commitment percentage in effect on the date on which indemnification is sought under this Section 10.2, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time be imposed on, incurred by or asserted against the Agent in any way relating to or arising out of, this Agreement, a Supplement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by the Agent under or in connection with any of the foregoing; The agreements in this Section shall survive the payment of each Loan and all other amounts payable hereunder. Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of any Lender or as Agent shall believe in good faith shall be necessary, under the circumstances or (ii) in the absence of its own gross negligence or willful misconduct.

 

20

 

 

10.3          Duties. Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 4 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent.

 

10.4          Reliance by Agent. Agent may rely, and shall be fully protected in acting, or refraining to act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed or presented by the proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper party or parties. In the absence of its gross negligence or willful misconduct, Agent may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to Agent and conforming to the requirements of the Loan Agreement or any of the other Loan Documents. Agent may consult with counsel, and any opinion or legal advice of such counsel shall be full and complete authorization and protection in respect of any action taken, not taken or suffered by Agent hereunder or under any Loan Documents in accordance therewith. Agent shall have the right at any time to seek instructions concerning the administration of the Collateral from any court of competent jurisdiction. Agent shall not be under any obligation to exercise any of the rights or powers granted to Agent by this Agreement, the Loan Agreement and the other Loan Documents at the request or direction of Lenders unless Agent shall have been provided by Lenders with adequate security and indemnity against the costs, expenses and liabilities that may be incurred by it in compliance with such request or direction.

 

10.5          Collateral Agent. The Agent shall also act as the “collateral agent” under the Loan Documents, and each of the Lenders hereby irrevocably appoints and authorizes the Agent to act as the agent of such Lender for purposes of acquiring, holding and enforcing any and all Liens on Collateral granted by Borrowers to secure any of the Obligations. Each Lender hereby authorizes Agent, on behalf of and for the ratable benefit of Lenders, in its capacity as collateral agent, to enter into any of the Loan Documents as secured party for purposes of acquiring, holding and enforcing all Liens on Collateral (and any other collateral from time to time securing the Obligations), and as Agent for and representative of Lender thereunder, and each Lender agrees to be bound by the terms of each such document. All powers, rights and remedies under the Loan Documents may be exercised solely by Agent, at the direction of the Required Lenders, for the benefit of Lenders and Agent in accordance with the terms thereof. In the event of a foreclosure on any of the Collateral pursuant to a public or private sale, either Agent or any Lender may be the purchaser of any or all of such Collateral at any such sale and Agent, as agent for and representative of Lenders (but not any Lender or Lenders in its or their respective individual capacities unless Required Lenders shall otherwise agree in writing) shall be entitled (subject to the proviso at the end of this sentence), for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral sold at any such public sale, to use and apply any of the Obligations as a credit on account of the purchase price for any Collateral payable by Agent at such sale; provided however, that neither Agent nor any Lender shall “credit bid” at any foreclosure and/or other public or private sale absent the consent of the Required Lenders. Without limiting the generality of the foregoing, Agent is hereby expressly authorized to execute any and all documents (including releases) that bind Lenders with respect to (i) the Collateral and the rights of Lenders with respect thereto, as contemplated by and in accordance with the provisions of the Loan Documents, and (ii) any other subordination agreement with respect to any Subordinated Debt.

 

10.6          Successor Agents. Agent may resign upon thirty (30) days’ notice to the Lenders and Borrowers. If Agent shall resign in its capacity under this Agreement and the other Loan Documents, then the Required Lenders shall appoint a successor agent, whereupon such successor agent shall succeed to the rights, powers and duties of Agent in its capacity, and the term “Agent” shall mean such successor agent effective upon such appointment and approval, and the former Agent’s rights, powers and duties as Agent in its capacity shall be terminated, without any other or further act or deed on the part of such former Agent or any of the parties to this Agreement or any Lender. If no applicable successor agent has accepted appointment as such Agent in its capacity by the date that is twenty (20) days following such retiring Agent’s notice of resignation, such retiring Agent’s resignation shall nevertheless thereupon become effective and the Lenders shall assume and perform all of the duties of such Agent hereunder until such time, if any, as the Required Lenders appoint a successor agent as provided for above. After any retiring Agent’s resignation as Agent, the provisions of this Section 10 shall inure to its benefit as to any actions taken or omitted to be taken by it while it was an Agent under this Agreement and the other Loan Documents.

 

21

 

 

ARTICLE 11 - DEFINITIONS

 

The definitions appearing in this Agreement or any Supplement shall be applicable to both the singular and plural forms of the defined terms:

 

Accountmeans any “account,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest and, in any event, shall include, without limitation, all accounts receivable, book debts and other forms of obligations (other than forms of obligations evidenced by Chattel Paper, Documents or Instruments) now owned or hereafter received or acquired by or belonging or owing to Borrower (including, without limitation, under any trade name, style or division thereof) whether arising out of goods sold or services rendered by Borrower or from any other transaction, whether or not the same involves the sale of goods or services by Borrower (including, without limitation, any such obligation that may be characterized as an account or contract right under the UCC) and all of Borrower’s rights in, to and under all purchase orders or receipts now owned or hereafter acquired by it for goods or services, and all of Borrower’s rights to any goods represented by any of the foregoing (including, without limitation, unpaid seller’s rights of rescission, replevin, reclamation and stoppage in transit and rights to returned, reclaimed or repossessed goods), and all monies due or to become due to Borrower under all purchase orders and contracts for the sale of goods or the performance of services or both by Borrower or in connection with any other transaction (whether or not yet earned by performance on the part of Borrower), now in existence or hereafter occurring, including, without limitation, the right to receive the proceeds of said purchase orders and contracts, and all collateral security and guarantees of any kind given by any Person with respect to any of the foregoing.

 

Account Control Agreementmeans (i) any control agreement entered into among the depository institution at which a Borrower or any Subsidiary maintains a Deposit Account or the securities intermediary or commodity intermediary at which a Borrower or any Subsidiary maintains a Securities Account or a Commodity Account, pursuant to which Agent, for the benefit of Lenders, obtains control (within the meaning of the UCC) over such Deposit Account, Securities Account, or Commodity Account or (ii) with respect to any foreign-denominated account, such agreement(s) as may be necessary to obtain a perfected first priority security interest in favor of Agent therein.

 

Affiliatemeans any Person which directly or indirectly controls, is controlled by, or is under common control with Borrower. “Control,” “controlled by” and “under common control with” mean direct or indirect possession of the power to direct or cause the direction of management or policies (whether through ownership of voting securities, by contract or otherwise); provided, that control shall be conclusively presumed when any Person or affiliated group directly or indirectly owns ten percent (10%) or more of the securities having ordinary voting power for the election of directors of a corporation.

 

Agreementmeans this Loan and Security Agreement and each Supplement thereto, as each may be amended or supplemented from time to time.

 

Bankruptcy Code means the Federal Bankruptcy Reform Act of 1978 (11 U.S.C. §101, et seq.), as amended.

 

Basic Interest means the rate of interest payable on the outstanding balance of each Loan at the applicable Designated Rate.

 

Borrowing Date means the Business Day on which the proceeds of a Loan are disbursed by any Lender.

 

Borrowing Request means a written request from Borrower in substantially the form of Exhibit “B” to the Supplement, requesting the funding of one or more Loans on a particular Borrowing Date.

 

Business Day means any day other than a Saturday, Sunday or other day on which commercial banks in New York City or San Francisco are authorized or required by law to close.

 

Change of Control means: (a) any sale, license, or other disposition of all or substantially all of the assets of Borrower; (b) any reorganization, consolidation, merger or other transaction involving Borrower; or (c) any transaction or series of related transactions in which any Person or two or more affiliated Persons acting in concert shall have acquired by contract or otherwise, the power to control the management of Borrower, or to control the equity interests of Borrower entitled to vote for members of the Board of Directors or equivalent governing body of Borrower on a fully-diluted basis (and taking into account all such securities that such Person or Persons have the right to acquire pursuant to any option right) representing 50% or more of the combined voting power of such securities (other than in connection with a Qualified Public Offering or a sale to recognized venture capital investors in a transaction or series of transactions effected by Borrower for financing purposes, so long as Borrower identifies to Agent and each Lender the venture capital investors prior to the closing of the transaction and provides Agent and each Lender with a description of the material terms of such transaction).

 

22

 

 

Chattel Paper means any “chattel paper,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Closing Date means the date of this Agreement.

 

Collateralmeans all of Borrower’s right, title and interest in and to the following property, whether now owned or hereafter acquired and wherever located: (a) all Receivables; (b) all Equipment; (c) all Fixtures; (d) all General Intangibles; (e) all Inventory; (f) all Investment Property; (g) all Deposit Accounts; (h) all Shares; (i) all other Goods and personal property of Borrower, whether tangible or intangible and whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located; (j) all Records; and (k) all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing.

 

Notwithstanding the foregoing the term “Collateral” shall not include: (i) more than sixty-five percent (65%) of the issued and outstanding capital stock, membership units or other securities entitled to vote owned or held of record by Borrower in any Subsidiary that is a controlled foreign corporation (as defined in the Internal Revenue Code), provided that the Collateral shall include one hundred percent (100%) of the issued and outstanding non-voting capital stock of such Subsidiary; (ii) “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such “intent to use” trademarks would be contrary to applicable law; or (iii) any contract, Instrument or Chattel Paper in which Borrower has any right, title or interest if and to the extent such contract, Instrument or Chattel Paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Borrower therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, Instrument or Chattel Paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (A) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, Instrument or Chattel Paper, or (B) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided, further, that immediately upon the ineffectiveness, lapse or termination of any such provision, the term “Collateral” shall include, and Borrower shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, Instrument or Chattel Paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Agent’s unconditional continuing security interest in and to all rights, title and interests of Borrower in or to any payment obligations or other rights to receive monies due or to become due under any such contract, Instrument or Chattel Paper and in any such monies and other proceeds of such contract, Instrument or Chattel Paper.

 

Commitmentmeans the obligation of each Lender to make Loans to Borrower up to the aggregate principal amount set forth in the Supplement.

 

Copyright Licensemeans any written agreement granting any right to use any Copyright or Copyright registration now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Copyrightsmeans all of the following now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest: (i) all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; (ii) all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, any State thereof or any other country; (iii) all continuations, renewals or extensions thereof; and (iv) any registrations to be issued under any pending applications.

 

23

 

 

Defaultmeans an event which with the giving of notice, passage of time, or both would constitute an Event of Default.

 

Default Rate means the applicable Designated Rate plus five percent (5%) per annum.

 

Deposit Accounts means any “deposit accounts,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Designated Rate means the rate of interest per annum described in the Supplement as being applicable to an outstanding Loan from time to time.

 

Documentsmeans any “documents,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Dollarsor $ means lawful currency of the United States.

 

Environmental Laws means all federal, state or local laws, statutes, common law duties, rules, regulations, ordinances and codes, together with all administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any governmental authorities, in each case relating to environmental, health, or safety matters.

 

Equipmentmeans any “equipment,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest and any and all additions, substitutions and replacements of any of the foregoing, wherever located, together with all attachments, components, parts, equipment and accessories installed thereon or affixed thereto.

 

Event of Default means any event described in Section 7.1.

 

Fixturesmeans any “fixtures,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

[*]

 

GAAPmeans generally accepted accounting principles and practices consistent with those principles and practices promulgated or adopted by the Financial Accounting Standards Board and the Board of the American Institute of Certified Public Accountants, their respective predecessors and successors. Each accounting term used but not otherwise expressly defined herein shall have the meaning given it by GAAP.

 

General Intangibles means any “general intangibles,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest and, in any event, shall include, without limitation, all right, title and interest that Borrower may now or hereafter have in or under any contract, all customer lists, Copyrights, Trademarks, Patents, websites, domain names, and all applications therefor and reissues, extensions, or renewals thereof, other items of, and rights to, Intellectual Property, interests in partnerships, joint ventures and other business associations, Licenses, permits, trade secrets, proprietary or confidential information, inventions (whether or not patented or patentable), technical information, procedures, designs, knowledge, know-how, software, data bases, data, skill, expertise, recipes, experience, processes, models, drawings, materials and records, goodwill (including, without limitation, the goodwill associated with any Trademark, Trademark registration or Trademark licensed under any Trademark License), claims in or under insurance policies, including unearned premiums, uncertificated securities, money, cash or cash equivalents, deposit, checking and other bank accounts, rights to sue for past, present and future infringement of Copyrights, Trademarks and Patents, rights to receive tax refunds and other payments and rights of indemnification.

 

Goodsmeans any “goods,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

[*]

 

Indebtednessof any Person means at any date, without duplication and without regard to whether matured or unmatured, absolute or contingent: (i) all obligations of such Person for borrowed money; (ii) all obligations of such Person evidenced by bonds, debentures, notes, or other similar instruments; (iii) all obligations of such Person to pay the deferred purchase price of property or services, except trade accounts payable arising in the ordinary course of business; (iv) all obligations of such Person as lessee under capital leases; (v) all obligations of such Person to reimburse or prepay any bank or other Person in respect of amounts paid under a letter of credit, banker’s acceptance, or similar instrument, whether drawn or undrawn; (vi) all obligations of such Person to purchase securities which arise out of or in connection with the sale of the same or substantially similar securities; (vii) all obligations of such Person to purchase, redeem, exchange, convert or otherwise acquire for value any capital stock of such Person or any warrants, rights or options to acquire such capital stock, now or hereafter outstanding, except to the extent that such obligations remain performable solely at the option of such Person; (viii) all obligations to repurchase assets previously sold (including any obligation to repurchase any accounts or chattel paper under any factoring, receivables purchase, or similar arrangement); (ix) obligations of such Person under interest rate swap, cap, collar or similar hedging arrangements; and (x) all obligations of others of any type described in clause (i) through clause (ix) above guaranteed by such Person.

 

24

 

 

Insolvency Proceedingmeans with respect to a Person (a) any case, action or proceeding before any court or other governmental authority relating to bankruptcy, reorganization, insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors with respect to such Person, or (b) any general assignment for the benefit of creditors, composition, marshalling of assets for creditors, or other, similar arrangement in respect of such Person’s creditors generally or any substantial portion of its creditors, undertaken under U.S. Federal, state or foreign law, including the Bankruptcy Code, but in each case, excluding any avoidance or similar action against such Person commenced by an assignee for the benefit of creditors, bankruptcy trustee, debtor in possession, or other representative of another Person or such other Person’s estate.

 

Instrumentsmeans any “instrument,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Intellectual Propertymeans all of Borrower’s Copyrights, Trademarks, Patents, Licenses, trade secrets, source codes, customer lists, proprietary or confidential information, inventions (whether or not patented or patentable), technical information, procedures, designs, knowledge, know-how, software, data bases, skill, expertise, experience, processes, models, drawings, materials, records and goodwill associated with the foregoing.

 

Intellectual Property Security Agreement means any Intellectual Property Security Agreement executed and delivered by Borrower in favor of Agent, as the same may be amended, supplemented, or restated from time to time.

 

Inventorymeans any “inventory,” as such term is defined in the UCC, wherever located, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest, and, in any event, shall include, without limitation, all inventory, goods and other personal property that are held by or on behalf of Borrower for sale or lease or are furnished or are to be furnished under a contract of service or that constitute raw materials, work in process or materials used or consumed or to be used or consumed in Borrower’s business, or the processing, packaging, promotion, delivery or shipping of the same, and all finished goods, whether or not the same is in transit or in the constructive, actual or exclusive possession of Borrower or is held by others for Borrower’s account, including, without limitation, all goods covered by purchase orders and contracts with suppliers and all goods billed and held by suppliers and all such property that may be in the possession or custody of any carriers, forwarding agents, truckers, warehousemen, vendors, selling agents or other Persons.

 

Investment Propertymeans any “investment property,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Letter of Credit Rights means any “letter of credit rights,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest, including any right to payment under any letter of credit.

 

Licensemeans any Copyright License, Patent License, Trademark License or other license of rights or interests now held or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest and any renewals or extensions thereof.

 

Lienmeans any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, any lease in the nature of a security interest, and the filing of any financing statement (other than a precautionary financing statement with respect to a lease that is not in the nature of a security interest) under the UCC or comparable law of any jurisdiction.

 

Loanmeans an extension of credit by each Lender under this Agreement.

 

25

 

 

Loan Documents means, individually and collectively, this Loan and Security Agreement, each Supplement, each Note, the Intellectual Property Security Agreements, and any other security or pledge agreement(s), any Warrant issued by Borrower in connection with this Agreement, and all other contracts, instruments, addenda and documents executed in connection with this Agreement or the extensions of credit which are the subject of this Agreement.

 

LTM Product Revenue means, as of the last day of any calendar month, Borrower’s Product Revenue (as defined in the Supplement) for the trailing twelve (12) month period ending on such date.

 

Material Adverse Effect or “Material Adverse Change” means (a) a material adverse change in, or a material adverse effect upon, the operations, business, properties, or financial condition of Borrower and its Subsidiaries, taken as a whole; (b) a material impairment of the ability of Borrower to perform under any Loan Document; or (c) a material adverse effect upon the legality, validity, binding effect or enforceability against Borrower of any Loan Document.

 

Notemeans a promissory note substantially in the form attached to the Supplement as Exhibit “A”, executed by Borrower evidencing each Loan.

 

Obligationsmeans all debts, obligations and liabilities of Borrower to each Lender or Agent now or hereafter made, incurred or created under, pursuant to or in connection with this Agreement or any other Loan Document (other than the Warrants), whether voluntary or involuntary and however arising or evidenced, whether direct or acquired by such Lender or Agent by assignment or succession, whether due or not due, absolute or contingent, liquidated or unliquidated, determined or undetermined, and whether Borrower may be liable individually or jointly, or whether recovery upon such debt may be or become barred by any statute of limitations or otherwise unenforceable; and all renewals, extensions and modifications thereof; and all attorneys’ fees and costs incurred by each Lender and Agent in connection with the collection and enforcement thereof as provided for in any such Loan Document.

 

Patent License means any written agreement granting any right with respect to any invention on which a Patent is in existence now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Patentsmeans all of the following property now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest: (a) all letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; (b) all reissues, continuations, continuations-in-part or extensions thereof; (c) all petty patents, divisionals, and patents of addition; and (d) all patents to be issued under any such applications.

 

Permitted Indebtedness means:

 

(a)             Indebtedness incurred for the acquisition of supplies, inventory or other property or services on normal trade credit;

 

(b)             Indebtedness incurred pursuant to one or more transactions permitted under Section 6.4;

 

(c)             Indebtedness of Borrower under this Agreement;

 

(d)             Subordinated Debt;

 

(e)             any Indebtedness approved by Agent and each Lender prior to the Closing Date as shown on Schedule 6.1;

 

(f)             Indebtedness secured by a Lien described in clause (c) of the defined term “Permitted Liens” not to exceed One Hundred Thousand Dollars ($100,000) in aggregate principal amount outstanding at any time;

 

(g)             Indebtedness incurred under corporate credit cards not to exceed (i) One Hundred Fifty Thousand Dollars ($150,000) in aggregate principal amount outstanding at any time prior to achievement of the Tranche 2 Availability Milestone, and (ii) Five Hundred Thousand Dollars ($500,000) in aggregate principal amount outstanding at any time after achievement of the Tranche 2 Availability Milestone;

 

(h)             guaranties and similar surety obligations in respect of Indebtedness otherwise constituting Permitted Indebtedness;

 

(i)            Indebtedness (in the aggregate outstanding amount of up to Five Hundred Thousand Dollars ($500,000) at any given time) incurred to finance insurance premiums in the ordinary course of business;

 

26

 

 

(j)             Indebtedness (in the aggregate outstanding amount of up to One Hundred Thousand Dollars ($100,000) at any given time) incurred as a result of endorsing negotiable instruments received in the ordinary course of business; and

 

(k)            extensions, refinancings and renewals of any of the foregoing; provided that the principal amount thereof is not increased.

 

Permitted Investment means:

 

(a)             accounts receivable in the ordinary course of Borrower’s business;

 

(b)             Investments in domestic certificates of deposit issued by, and other domestic investments with, financial institutions organized under the laws of the United States or a state thereof, having at least One Hundred Million Dollars ($100,000,000) in capital and a rating of at least “investment grade” or “A” by Moody’s or any successor rating agency;

 

(c)             Investments in marketable obligations of the United States of America and in open market commercial paper given the highest credit rating by a national credit agency and maturing not more than one year from the creation thereof;

 

(d)             temporary advances to cover incidental expenses to be incurred in the ordinary course of business;

 

(e)             Investments in joint ventures, strategic alliances, licensing and similar arrangements customary in Borrower’s industry and which do not require Borrower to assume or otherwise become liable for the obligations of any third party not directly related to or arising out of such arrangement or, without the prior written consent of Agent and each Lender, require Borrower to transfer ownership of non-cash assets to such joint venture or other entity;

 

(f)              Investments in (i) one or more wholly-owned domestic direct or indirect Subsidiaries of Parent so long as in accordance with Section 6.14(a) of this Agreement, each such Person has been made a co-borrower hereunder or has executed and delivered to Agent an agreement, in form and substance reasonably satisfactory to Agent, containing a guaranty of the Obligations, and (ii) one or more direct or indirect foreign Subsidiaries of Parent in an aggregate amount of One Million Dollars ($1,000,000) on a net basis (i.e. Investments net of any payments received by Borrower from foreign Subsidiaries after the making of such Investments) at any time;

 

(g)             Investments approved by Agent and each Lender prior to the Closing Date as shown on Schedule 6.6;

 

(h)             Investments accepted in connection with Transfers permitted by Section 6.5;

 

(i)              non-cash loans approved by Borrower’s Board of Directors to employees, officers or directors relating to the purchase of equity securities of Borrower pursuant to employee stock purchase plans or agreements approved by Borrower’s Board of Directors, limited to an aggregate total of One Hundred Thousand Dollars ($100,000) at any time outstanding;

 

(j)              Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business;

 

(k)            Investments permitted under Section 6.11;

 

(l)             Investments consisting of notes receivable of, or prepaid royalties and other credit extensions to, customers and suppliers in the ordinary course of business; and

 

(m)           Investments by wholly owned Subsidiaries in other wholly owned Subsidiaries or in Borrower.

 

Permitted Lien means:

 

(n)             licenses or sublicenses of Intellectual Property in accordance with the terms of Section 6.5 hereof;

 

(a)             involuntary Liens which, in the aggregate, would not have a Material Adverse Effect and which in any event would not exceed, in the aggregate, the Threshold Amount;

 

(b)             Liens for current taxes or other governmental or regulatory assessments which are not delinquent, or which are contested in good faith by the appropriate procedures and for which appropriate reserves are maintained;

 

27

 

 

(c)             security interests on any property held or acquired by Borrower in the ordinary course of business securing Indebtedness incurred or assumed for the purpose of financing all or any part of the cost of acquiring such property; provided, that such Lien attaches solely to the property acquired with such Indebtedness and that the principal amount of such Indebtedness does not exceed one hundred percent (100%) of the cost of such property;

 

(d)             Liens in favor of Agent;

 

(e)             bankers’ liens, rights of setoff and similar Liens incurred on deposits made in the ordinary course of business as long as an Account Control Agreement (or equivalent) for each account in which such deposits are held in a form acceptable to Agent has been executed and delivered to Agent to the extent required under Section 6.11;

 

(f)             materialmen’s, mechanics’, repairmen’s, warehousemen’s, carriers’, landlord’s (subject to Section 5.9(e) hereof), employees’ or other like Liens arising in the ordinary course of business and which are not delinquent for more than 45 days or are being contested in good faith by appropriate proceedings;

 

(g)             any judgment, attachment or similar Lien, unless the judgment it secures exceeds the Threshold Amount and has not been discharged or execution thereof effectively stayed and bonded against pending appeal within thirty (30) days of the entry thereof;

 

(h)            Liens securing Subordinated Debt;

 

(i)             Liens which have been approved by Agent and each Lender in writing prior to the Closing Date, as shown on Schedule 6.2 hereto;

 

(j)             the interests of licensors under inbound licenses to Borrower;

 

(k)            the interests of sub-lessees under subleases of real property;

 

(l)             Liens to secure payment of workers’ compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA);

 

(m)           deposits to secure the performance of bids, trade contracts (other than for Indebtedness), leases (other than capital lease obligations), statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature arising as a matter of law and incurred in the ordinary course of business; and

 

(n)             zoning restrictions, easements, rights of way, restrictions on use of real property and other similar encumbrances incurred in the ordinary course of business which, in the aggregate, are not substantial in amount and do not materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of the Borrower or any of its Subsidiaries.

 

Personmeans any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, public benefit corporation, other entity or government (whether federal, state, county, city, municipal, local, foreign, or otherwise, including any instrumentality, division, agency, body or department thereof).

 

Proceedsmeans “proceeds,” as such term is defined in the UCC and, in any event, shall include, without limitation, (a) any and all Accounts, Chattel Paper, Instruments, cash or other forms of money or currency or other proceeds payable to Borrower from time to time in respect of the Collateral, (b) any and all proceeds of any insurance, indemnity, warranty or guaranty payable to Borrower from time to time with respect to any of the Collateral, (c) any and all payments (in any form whatsoever) made or due and payable to Borrower from time to time in connection with any requisition, confiscation, condemnation, seizure or forfeiture of all or any part of the Collateral by any governmental authority (or any Person acting under color of governmental authority), (d) any claim of Borrower against third parties (i) for past, present or future infringement of any Copyright, Patent or Patent License or (ii) for past, present or future infringement or dilution of any Trademark or Trademark License or for injury to the goodwill associated with any Trademark, Trademark registration or Trademark licensed under any Trademark License and (e) any and all other amounts from time to time paid or payable under or in connection with any of the Collateral.

 

[*]

 

Receivablesmeans all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, and letters of credit and Letter of Credit Rights.

 

28

 

 

Recordsmeans all Borrower’s computer programs, software, hardware, source codes and data processing information, all written documents, books, invoices, ledger sheets, financial information and statements, and all other writings concerning Borrower’s business.

 

Related Person means any Affiliate of Borrower, or any officer, employee, director or equity security holder of Borrower or any Affiliate.

 

Required Lendersmeans the Lenders holding at least sixty six percent (66%) of the aggregate principal balance of the Loans.

 

Restricted Accountmeans an interest-bearing restricted deposit account maintained by Borrower solely for holding the portion of the Tranche 1 proceeds funded to such account by Lenders. The Restricted Account shall be subject to a blocked Account Control Agreement at all times.

 

Rights to Payment means all Borrower’s accounts, instruments, contract rights, documents, chattel paper and all other rights to payment, including, without limitation, the Accounts, all negotiable certificates of deposit and all rights to payment under any Patent License, any Trademark License, or any commercial or standby letter of credit.

 

Security Documents means this Loan and Security Agreement, the Supplement hereto, the Intellectual Property Security Agreement, and any and all Account Control Agreements, collateral assignments, chattel mortgages, financing statements, amendments to any of the foregoing and other documents from time to time executed or filed to create, perfect or maintain the perfection of Agent’s Liens on the Collateral.

 

Sharesmeans: (a) one hundred percent (100%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by Borrower in any Subsidiary that is not a controlled foreign corporation (as defined in the Internal Revenue Code), and (b) 65% of the issued and outstanding capital stock, membership units or other securities entitled to vote owned or held of record by Borrower in any Subsidiary that is a controlled foreign corporation (as defined in the Internal Revenue Code).

 

Subordinated Debt means Indebtedness (i) approved by Required Lenders; and (ii) where the holder’s right to payment of such Indebtedness, the priority of any Lien securing the same, and the rights of the holder thereof to enforce remedies against Borrower following default have been made subordinate to the Liens of Agent and to the prior payment to each Lender of the Obligations, either (A) pursuant to a written subordination agreement approved by Required Lenders in their sole but reasonable discretion or (B) on terms otherwise approved by Required Lenders in their sole but reasonable discretion.

 

Subsidiarymeans any Person a majority of the equity ownership or voting stock of which is directly or indirectly now owned or hereafter acquired by Borrower or by one or more other Subsidiaries.

 

Supplementmeans that certain supplement to the Loan and Security Agreement, as the same may be amended or restated from time to time, and any other supplements entered into between Borrower, Agent and each Lender, as the same may be amended or restated from time to time.

 

Supporting Obligations means any “supporting obligations,” as such term is defined in the UCC, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Termination Date has the meaning specified in the Supplement.

 

Threshold Amount has the meaning specified in the Supplement.

 

Trademark License means any written agreement granting any right to use any Trademark or Trademark registration now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

Trademarksmeans all of the following property now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest: (a) all trademarks, tradenames, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof and (b) reissues, extensions or renewals thereof.

 

UCCmeans the Uniform Commercial Code as the same may, from time to time, be in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Agent’s Lien on any Collateral is governed by the Uniform Commercial Code as enacted and in effect in a jurisdiction other than the State of California, the term “UCC” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. Unless otherwise defined herein, terms that are defined in the UCC and used herein shall have the meanings given to them in the UCC.

 

Warranthas the meaning specified in the Supplement.

 

[Signature page follows]

 

29

 

 

[Signature page to Loan and Security Agreement]

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

   
BORROWER:  
   
CYTOSORBENTS CORPORATION  
   
By: /s/ Phillip P. Chan  
Name: Phillip P. Chan, MD, Ph.D.  
Title: Chief Executive Officer  
   
CYTOSORBENTS MEDICAL INC.  
   
By: /s/ Phillip P. Chan  
Name: Phillip P. Chan, MD, Ph.D.  
Title: Chief Executive Officer  
   
AGENT:  
   
AVENUE CAPITAL MANAGEMENT II, L.P.  
   
By: Avenue Capital Management II GenPar, LLC  
Its: General Partner  
   
By: /s/ Sonia Gardner  
Name: Sonia Gardner  
Title: Member  
   
LENDERS:  
   
AVENUE VENTURE OPPORTUNITIES FUND, L.P.  
   
By: Avenue Venture Opportunities Partners, LLC  
Its: General Partner  
   
By: /s/ Sonia Gardner  
Name: Sonia Gardner  
Title: Authorized Signatory  
   
AVENUE VENTURE OPPORTUNITIES FUND II, L.P.  
   
By: Avenue Venture Opportunities Partners II, LLC  
Its: General Partner  
   
By: /s/ Sonia Gardner  
Name: Sonia Gardner  
Title: Authorized Signatory  

 

 

EX-10.2 3 tm2418904d1_ex10-2.htm EXHIBIT 10.2

Exhibit 10.2

 

Certain portions of this exhibit have been redacted because the information is both (i) not material and (ii) the type that the registrant treats as private or confidential. Redacted information has been noted in this document with a placeholder identified by the mark “[*]”.

 

SUPPLEMENT

to the

Loan and Security Agreement

dated as of June 28, 2024

among

 

CYTOSORBENTS CORPORATION (“Parent”)

and

 

CYTOSORBENTS MEDICAL INC.

(“Medical”; and together with Parent,

jointly and severally, individually and collectively, “Borrower”)

 

AVENUE CAPITAL MANAGEMENT II, L.P.,

a Delaware limited partnership,

as administrative agent and collateral agent (in such capacity “Agent”)

and

 

AVENUE VENTURE OPPORTUNITIES FUND, L.P. II,

a Delaware limited partnership (“Avenue 2”), as a lender

and

 

AVENUE VENTURE OPPORTUNITIES FUND, L.P.,

a Delaware limited partnership (“Avenue”), as a lender

(together with Avenue 2, each a “Lender” and collectively, “Lenders”)

 

 

This is a Supplement identified in the document entitled Loan and Security Agreement, dated as of June 28, 2024 (as amended, restated, supplemented and modified from time to time, the “Loan and Security Agreement”), by and among Borrower, Lenders and Agent. All capitalized terms used in this Supplement and not otherwise defined in this Supplement have the meanings ascribed to them in Article 10 of the Loan and Security Agreement, which is incorporated in its entirety into this Supplement. In the event of any inconsistency between the provisions of the Loan and Security Agreement and this Supplement, this Supplement is controlling.

 

In addition to the provisions of the Loan and Security Agreement, the parties agree as follows:

 

Part 1 - Additional Definitions:

 

“Amortization Period” means the period commencing on the first day of the first full calendar month following the Interest-only Period and continuing until the Maturity Date.

 

“Commitment” means, subject to the terms and conditions set forth in the Loan and Security Agreement and this Supplement, Lenders’ commitment to make Growth Capital Loans to Borrower up to an aggregate original principal amount of Twenty Million Dollars ($20,000,000) (“Tranche 1”), with Four Million Five Hundred Thousand Dollars ($4,500,000) funded by Avenue and Ten Million Five Hundred Thousand Dollars ($10,500,000) funded by Avenue 2 on the Closing Date and up to Five Million Dollars ($5,000,000) to be funded between July 1, 2025 and December 31, 2025 subject to the conditions in Section 1(a)(i) of Part 2 (“Tranche 2”).

 

 

 

 

“Designated Rate” means, for each Growth Capital Loan, a variable rate of interest per annum equal to the greater of (A) the Prime Rate plus five percent (5.00%) and (B) thirteen and one half percent (13.50%). Changes to the Designated Rate based on changes to the Prime Rate shall be effective as of the next scheduled interest payment date immediately following such change.

 

FDA” means the United States Food and Drug Administration or any successor thereto.

 

“Final Payment” means a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) equal to four and one-half percent (4.50%) of the original Commitment amount of Twenty Million Dollars ($20,000,000).

 

“Growth Capital Loan” means any Loan requested by Borrower and funded by a Lender under its Commitment for general corporate purposes of Borrower, including, without limitation, the repayment of certain Indebtedness of Borrower to Western Alliance Bank.

 

“Interest-only Milestone” means Borrower has (i) achieved the Tranche 2 Availability Milestone and (ii) achieved, for the trailing six (6) month period ending June 30, 2026, at least [*] in Product Revenue; all based upon written evidence thereof provided to, and in form and content reasonably acceptable to, and reviewed and approved by Agent in its reasonable discretion.

 

“Interest-only Period” means the period commencing on the Closing Date and continuing until the twenty four (24) month anniversary of the Closing Date; provided, however, that such period shall be extended for six (6) months if as of the last day of the Interest-only Period then in effect Borrower has achieved the Interest-only Milestone; provided, further, that the Interest-only Period shall not exceed thirty (30) months; provided, further, however, that no extension of the Interest-only Period shall be available if as of the last day of the Interest-only Period then in effect an Event of Default shall have occurred and be continuing.

 

“Loan” or “Loans” mean, as the context may require, individually a Growth Capital Loan, and collectively, the Growth Capital Loans.

 

“Loan Commencement Date” means, with respect to each Growth Capital Loan: (a) the first day of the first full calendar month following the Borrowing Date of such Loan if such Borrowing Date is not the first day of a month; or (b) the same day as the Borrowing Date if the Borrowing Date is the first day of a month.

 

“Maturity Date” means July 1, 2027; provided, however, “Maturity Date” shall mean January 1, 2028, if Borrower draws the full amount of Tranche 2 by December 31, 2025.

 

“Prepayment Fee” means, with respect to any prepayment of the Loans:

 

(i)          if the prepayment occurs during the period commencing on the Closing Date and ending on (and including) the one-year anniversary of the Closing Date, an amount equal to the principal amount of the Loans prepaid multiplied by three percent (3.00%);

 

(ii)         if the prepayment occurs during the period commencing on the day immediately following the one-year anniversary of the Closing Date and ending on (and including) the two-year anniversary of the Closing Date, an amount equal to the principal amount of the Loans prepaid multiplied by two percent (2.00%); and

 

(iii)        if the prepayment occurs at any time after the date immediately following the two-year anniversary of the Closing Date, an amount equal to the principal amount of the Loans prepaid multiplied by one percent (1.00%).

 

“Prime Rate” is the rate of interest per annum from time to time published in the money rates section of The Wall Street Journal or any successor publication thereto as the “prime rate” then in effect; provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Supplement; and provided further that if such rate of interest, as set forth from time to time in the money rates section of The Wall Street Journal, becomes unavailable for any reason as determined by Agent, the “Prime Rate” shall mean the rate of interest per annum announced by Wells Fargo Bank as its prime rate in effect at its principal office in the State of California (such announced Prime Rate not being intended to be the lowest rate of interest charged by such institution in connection with extensions of credit to debtors); provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Supplement.

 

2

 

 

“Product Revenue” means, for any month, Borrower’s total Revenue (excluding any Revenue derived from licensing agreements) from the sale of products for such month determined on a consolidated basis in accordance with GAAP.

 

“Restricted Account Milestone” means, on or before March 31, 2025, (i) the FDA has accepted Borrower’s application for review with respect to DrugSorb-ATR De Novo 510(k) and (ii) Borrower has received at least Three Million Dollars ($3,000,000) in net proceeds from the sale of its equity securities after the Closing Date.

 

“Revenue” means, as of any date of determination, Borrower’s revenue determined in accordance with GAAP.

 

“Termination Date” means the earlier of: (i) the date Lender may terminate making Growth Capital Loans or extending other credit pursuant to the rights of Lender under Article 7 of the Loan and Security Agreement; and (ii) December 31, 2025.

 

Tranche 2 Availability Milestone” means Borrower shall have received clearance from the FDA to market its “DrugSorb-ATR System” (or similar name), all based upon written evidence thereof provided to, and in form and content reasonably acceptable to, and reviewed and approved by Agent in its reasonable discretion; provided, however, Tranche 2 shall not be made available if on the date of the occurrence of the Tranche 2 Availability Milestone an Event of Default has occurred and is continuing.

 

“Threshold Amount” means Two Hundred Fifty Thousand Dollars ($250,000).

 

“Warrant” is defined in Part 2, Section 3(a) hereof.

 

Part 2 - Additional Covenants and Conditions:

 

1.            Additional Condition(s) Precedent Regarding Growth Capital Loan Commitments. In addition to the satisfaction of all of the other applicable conditions precedent specified in Sections 4.1 and 4.2 of the Loan and Security Agreement and this Supplement, each Lender’s obligation to fund Tranche 2 of its Commitment of Growth Capital Loans is subject to receipt by Lender of evidence that the following conditions precedent have been satisfied, as determined by Lender in its sole discretion:

 

(i)          Borrower has achieved the Tranche 2 Availability Milestone; and

 

(ii)         no Event of Default shall have occurred and be continuing.

 

Subject to satisfaction of the conditions precedent specified in Sections 4.1 and Section 4.2 of the Loan and Security Agreement and this Supplement, each Lender agrees to make Growth Capital Loans to Borrower under Lender’s Commitment from time to time from and after the Closing Date up to and including the Termination Date in an aggregate, original principal amount up to, but not exceeding, then then-unfunded portion of such Lender’s Commitment.

 

(b)          Minimum Funding Amount; Maximum Number of Borrowing Requests; Restricted Account. Growth Capital Loans requested by Borrower to be made on a single Business Day shall be for a minimum aggregate, original principal amount of Two Million Five Hundred Thousand Dollars ($2,500,000) and Borrower shall not submit a Borrowing Request more frequently than once per calendar month without Agent’s prior consent; provided, however, that Tranche 1 shall be funded on the Closing Date; and provided, further, however, that Lenders shall bifurcate Tranche 1 on the Closing Date to fund (i) Ten Million Dollars ($10,000,000) to the primary operating account identified in Section 6(a) hereof and (ii) Five Million Dollars ($5,000,000) to the Restricted Account identified in Section 6(b) hereof. Upon Borrower’s achievement of the Restricted Account Milestone, Agent shall release the funds in the Restricted Account in a dollar amount equal to the equity proceeds received by Borrower pursuant clause (ii) of the definition of “Restricted Account Milestone.” From and after June 30, 2025, Borrower shall be permitted to direct Agent to release amounts on deposit in the Restricted Account to be applied to the prepayment of the Growth Capital Loans or other Obligations (Borrower acknowledges that the applicable Prepayment Fee and Final Payment shall applied in accordance with the terms hereof with respect to any prepayment of the Growth Capital Loans). In addition, all amounts on deposit in the Restricted Account on account of interest accrued on such deposits shall be automatically transferred to the Primary Operating Account on a monthly basis, so long as after giving effect to such transfer of accrued interest, the balance in the Restricted Account is not less than the Five Million Dollars ($5,000,000) or such lesser amount as may be required to be held in the Restricted Account after giving effect to any release as a result of Borrower’s achievement of the Restricted Account Milestone.

 

3

 

 

(c)          Repayment of Growth Capital Loans. Principal of, and interest on, each Growth Capital Loan shall be payable as set forth in a Note evidencing such Growth Capital Loan (substantially in the form attached hereto as Exhibit “A”), which Note shall provide substantially as follows: principal shall be fully amortized over the Amortization Period in equal, monthly principal installments plus, in each case, unpaid interest thereon at the Designated Rate, commencing after the Interest-only Period of interest-only installments at the Designated Rate. In particular, on the Borrowing Date applicable to such Growth Capital Loan, Borrower shall pay to Agent (i) if the Borrowing Date is earlier than the Loan Commencement Date, interest only at the Designated Rate, in advance, on the outstanding principal balance of the Growth Capital Loan for the period from the Borrowing Date through the last day of the calendar month in which such Borrowing Date occurs (it being understood that this clause (i) shall not apply in the case the Borrowing Date is on the same date as the Loan Commencement Date), and (ii) the first (1st) interest-only installment at the Designated Rate, in advance, on the outstanding principal balance of the Note evidencing such Loan for the ensuing month. Commencing on the first day of the second full month after the Borrowing Date and continuing on the first day of each month during the Interest-only Period thereafter, Borrower shall pay to Agent interest only at the Designated Rate, in advance, on the outstanding principal balance of the Loan evidenced by such Note for the ensuing month. Commencing on the first day of the first full month after the end of the Interest-only Period, and continuing on the first day of each consecutive calendar month thereafter, Borrower shall pay to Agent equal consecutive monthly principal installments in advance in an amount sufficient to fully amortize the Loan evidenced by such Note over the Amortization Period, plus interest at the Designated Rate for such month. On the Maturity Date, all principal and accrued interest then remaining unpaid and the Final Payment shall be due and payable.

 

2.            Prepayment. The Growth Capital Loans may be prepaid as provided in this Section 2 only. Borrower may prepay outstanding Growth Capital Loans in whole or in part, at any time upon no less than five (5) Business Days’ prior written notice to the Lenders, by tendering to each Lender a cash payment in respect of such Loans in an amount determined by such Lender equal to the sum of: (i) the outstanding principal amount of such Loans being prepaid, which such amount shall be at least Five Million Dollars ($5,000,000), except that, after June 30, 2025, such prepayment may also be made from amounts on deposit in the Restricted Account as described in Section 1(b) of this Part 2 in an amount less than Five Million Dollars ($5,000,000); (ii) the accrued and unpaid interest on such Loans as of the date of prepayment; (iii) the Prepayment Fee applicable to the principal amount of Loan being prepaid; and (iv)(x) in the case of a prepayment in full, the Final Payment (less any amount of the Final Payment prepaid pursuant to Part 2, Section 2(iv)(y) below in connection with any partial prepayment of the Loans), and (y) in the case of any partial prepayment, a portion of the Final Payment in an amount equal to four and one-half of one percent (4.50%) of the principal amount of Loans being prepaid; provided that, if a Lender has not yet exercised its rights under Section 3(d) hereof, Borrower shall provide written notice of prepayment at least five (5) Business Days in advance of the proposed prepayment date and such Lender shall have the option, with respect to the Conversion Option, to exercise its rights pursuant to Section 3(d) hereof by delivering written notice to Borrower at least two (2) Business Days in advance of the proposed prepayment date.

 

3.            Issuance of Warrant and Right to Invest; Conversion Right.

 

(a)          Warrant. As additional consideration for the making of its Commitment, each Lender has earned and is entitled to receive immediately upon the execution of the Loan and Security Agreement and this Supplement, a warrant instrument issued by Parent (the “Warrant”).

 

4

 

 

(b)          Warrant General. The Warrant shall be in form and substance reasonably satisfactory to the applicable Lender.

 

(c)          Right to Invest. Lenders shall have the right, in their respective discretion, but not the obligation, to invest an aggregate amount of up to One Million Dollars ($1,000,000) in equity securities of Parent on the same terms, conditions, and pricing offered by Parent to any investor existing at such time, in connection with any offering of Parent’s equity securities after the Closing Date; provided, however, (A) Parent shall deliver written notice to Agent of any transaction involving Parent’s equity securities at least ten (10) Business Days prior to the closing of such transaction; and (B) the terms shall exclude a board or observer seat on the Borrower’s Board of Directors, which may be offered to other investors at Borrower’s discretion, and any other terms that are not offered generally to all investors participating in such financing.

 

(i)          Conversion Right. Lenders shall have the right, in their respective discretion, but not the obligation, at any time and from time to time, while the Loan is outstanding, to convert an aggregate amount of up to Two Million Dollars ($2,000,000) of the principal amount of the outstanding Growth Capital Loans (the “Conversion Option”) into Parent’s common stock (the “Common Stock”) at a price per share equal to one hundred twenty percent (120.00%) of the Closing Price set forth (and as defined) in the Warrant (the “Conversion Price;” the exercise of such Conversion Option, a “Conversion”). The Conversion Option will be exercised by such Lender delivering a written, signed conversion notice to the Borrower in accordance with this Section 3(d) which will include (i) the date of which the conversion notice is given, (ii) a statement to the effect that the Lender is exercising the Conversion Option, (iii) the amount in respect of which the Conversion Option is being exercised and the number of shares issued and (iv) a date on which the allotment and issuance of the shares is to take place. For the avoidance of doubt, the shares of Common Stock issued pursuant to the Conversion shall be unrestricted and freely tradable (i) while a registration statement covering the resale of such shares is effective under the Securities Act or (ii) if such shares become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to SEC Rule 144.

 

4.            Commitment Fee. Borrower shall pay to each Lender, pro-rata in accordance with each Lender’s respective Commitment, a commitment fee in the amount of one percent (1.00%) of the total Commitment of such Lender, due and payable on the Closing Date, of which Once Hundred Thousand Dollars ($100,000) has been paid by Borrower to Avenue as an advance deposit prior to the date hereof. As an additional condition precedent under Section 4.1 of the Loan and Security Agreement, each Lender shall have completed to its satisfaction its due diligence review of Borrower’s business and financial condition and prospects, and such Lender’s pro rata share of the Commitment shall have been approved. If this condition is not satisfied, the One Hundred Thousand Dollar ($100,000) advance deposit previously paid by Borrower to Avenue shall be refunded. Except as set forth in this Section 4, the Commitment Fee is not refundable.

 

5.            Documentation Fee Payment. On the Closing Date, Borrower shall reimburse each Lender and Agent pursuant to Section 9.8(a) of the Loan and Security Agreement for (i) its reasonable attorneys’ fees, costs and expenses incurred in connection with the preparation and negotiation of the Loan Documents and (ii) such Lender’s and Agent’s costs and filing fees related to perfection of its Liens in the Collateral in any jurisdiction in which the same is located, recording a copy of the Intellectual Property Security Agreement with the United States Patent and Trademark Office or the United States Copyright Office, as applicable, and confirming the priority of such Liens.

 

6.            Account Information

 

(a)Borrower’s Primary Operating Account and Wire Transfer Instructions:

 

[*]

 

(b)Restricted Account Wire Transfer Instructions:

 

[*]

 

7.            Debits to Account for ACH Transfers. For purposes of Sections 2.2 and 5.10 of the Loan and Security Agreement, the Primary Operating Account shall be the bank account set forth in Section 6 above, unless and until such account is changed in accordance with Section 5.10 of the Loan and Security Agreement. Borrower hereby agrees that the Growth Capital Loans will be advanced to the account specified above and regularly scheduled payments of principal, interest and fees due to each Lender will be automatically debited by each Lender from the same account. Borrower hereby confirms that the bank at which the Primary Operating Account is maintained uses that same ABA Number for incoming wires transfers to the Primary Operating Account and outgoing ACH transfers from the Primary Operating Account.

 

5

 

 

Part 3 - Additional Representations:

 

Borrower represents and warrants that as of the Closing Date and, subject to any written updates of the information set forth below by Borrower to each Lender and Agent, each Borrowing Date:

 

a)Parent’s chief executive office is located at: 305 College Road East, Princeton, NJ 08540

 

b)Its Equipment is located at: 305 College Road East, Princeton, NJ 08540

 

c)Its Inventory is located at: 305 College Road East, Princeton, NJ 08540

 

d)Its Records are located at: 305 College Road East, Princeton, NJ 08540

 

e)In addition to Parent’s chief executive office, Borrower maintains offices or operates its business at the following locations: None.

 

f)Other than its full corporate name, Borrower has conducted business using the following trade names or fictitious business names: None.

 

g)Its state corporation identification numbers are: CytoSorbents Corporation (5629349); CytoSorbents Medical, Inc. (4109060)

 

h)Its U.S. federal tax identification numbers are: CytoSorbents Corporation (98-0373793); CytoSorbents Medical, Inc. (20-4496406)

 

i)Other than Borrower’s Primary Operating Account identified in Section 6(a) and the Restricted Account identified in Section 6(b) above, Borrower maintains the following Deposit Accounts and investment accounts:

 

[*]

 

Part 4 - Additional Loan Documents:

 

  Form of Promissory Note Exhibit “A”
  Form of Borrowing Request Exhibit “B”
  Form of Compliance Certificate Exhibit “C”

 

[Remainder of this page intentionally left blank; signature page follows]

 

6

 

 

[Signature page to Supplement to Loan and Security Agreement]

 

IN WITNESS WHEREOF, the parties have executed this Supplement as of the date first above written.

 

  BORROWER:
   
  CYTOSORBENTS CORPORATION
   
  By: /s/ Phillip P. Chan
  Name: Phillip P. Chan, MD, Ph.D.
  Title: Chief Executive Officer
   
  CYTOSORBENTS MEDICAL INC.
   
  By: /s/ Phillip P. Chan
  Name: Phillip P. Chan, MD, Ph.D.
  Title: Chief Executive Officer
   
Address for Notices: 305 College Road East
  Princeton, NJ 08540
  Attn: Chief Executive Officer
   
  AGENT:
   
  AVENUE CAPITAL MANAGEMENT II, L.P.
   
  By: Avenue Capital Management II GenPar, LLC
  Its: General Partner
   
  By: /s/ Sonia Gardner
  Name:  Sonia Gardner
  Title: Member
   
Address for Notices: 11 West 42nd Street, 9th Floor
  New York, New York 10036
  Attn: Todd Greenbarg, Senior Managing Director

 

 

 

 

LENDERS:
   
  AVENUE VENTURE OPPORTUNITIES FUND, L.P.
   
  By: Avenue Venture Opportunities Partners, LLC
  Its:  General Partner
   
  By:  /s/ Sonia Gardner
  Name: Sonia Gardner
  Title: Authorized Signatory
   
Address for Notices: 11 West 42nd Street, 9th Floor
  New York, New York 10036
  Attn: Todd Greenbarg, Senior Managing Director
   
  AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
   
  By: Avenue Venture Opportunities Partners II, LLC
  Its: General Partner
   
  By: /s/ Sonia Gardner
  Name: Sonia Gardner
  Title: Authorized Signatory
   
Address for Notices: 11 West 42nd Street, 9th Floor
  New York, New York 10036
  Attn: Todd Greenbarg, Senior Managing Director

 

 

 

EX-10.3 4 tm2418904d1_ex10-3.htm EXHIBIT 10.3

 

Exhibit 10.3

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OPINION OF COUNSEL IN A FORM REASONABLY ACCEPTABLE TO COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED DUE TO AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR (C) CYTOSORBENTS CORPORATION OTHERWISE SATISFIES ITSELF THAT SUCH TRANSACTION IS COMPLIANT WITH SUCH LAWS.

 

Date of Issuance: June 28, 2024

 

WARRANT TO PURCHASE

 

SHARES OF STOCK OF

 

CYTOSORBENTS CORPORATION

 

(Void after June 30, 2029)

 

This certifies that [AVENUE VENTURE OPPORTUNITIES FUND, LP]1, a Delaware limited partnership, or permitted assigns (“Holder”), for value received, is entitled to purchase from CYTOSORBENTS CORPORATION, a Delaware corporation (“Company”), the Applicable Number (hereinafter defined) of fully paid and nonassessable shares of the Company’s Common Stock (“Common Stock”), for cash, at a purchase price per share equal to the Exercise Price (hereinafter defined). Holder may also exercise this Warrant on a cashless or “net issuance” basis as described in Section 1(b) below, and this Warrant shall be deemed to have been exercised in full on such basis on the Expiration Date (hereinafter defined), to the extent not fully exercised prior to such date. This Warrant is issued in connection with that certain Loan and Security Agreement and Supplement thereto, both of even date herewith (as amended, restated and supplemented from time to time, the “Loan Agreement” and the “Supplement”, respectively), among Company, as borrower, AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership, as Agent, and Holder, as lender (“Lender”). Capitalized terms used herein and not otherwise defined in this Warrant shall have the meaning(s) ascribed to them in the Loan Agreement and the Supplement, unless the context would otherwise require.

 

Applicable Number” means 1,645,5692 (such amount sometimes referred to hereinafter as the “Coverage Amount”).

 

Closing Price” means $0.79.

 

Exercise Price” means the lower of the Closing Price or the Next Round Price (hereinafter defined).

 

Next Round Price” means the lowest effective price per share of any bona fide equity offering of the Common Stock after the Date of Issuance and prior to December 31, 2024; provided the sale of Common Stock in connection with any “at-the-market” facility in effect as of the Date of Issuance shall be excluded from the determination of any such Next Round Price. For clarity, if the Exercise Price is determined after the date hereof to be the “Next Round Price,” such determination shall have no effect on the Applicable Number, which shall be set on the date hereof and subject solely to adjustment under Section 4.1 or 4.6 hereof.

 

 

1 Warrant to be replicated for Avenue 2 upon agreement to terms of this Warrant.

2 Amount to be “split” based upon pro rata Commitment of Avenue and Avenue 2.

 

 

 

 

Trading Day” means a day when the New York Stock Exchange is open for trading in shares of the Common Stock.

 

5-day VWAP” means the volume-weighted average price of the Common Stock, determined for the five (5) consecutive Trading Days ending on the last Trading Day immediately preceding the applicable date, as reported by Bloomberg, L.P.

 

Subject to Section 4.3, this Warrant may be exercised at any time or from time to time up to and including 5:00 p.m. (Pacific time) on June 30, 2029 (the “Expiration Date”), upon surrender to Company at its principal office at 305 College Road East, Princeton, NJ 08540 (or at such other location as Company may advise Holder in writing) of this Warrant properly endorsed with the Form of Subscription attached hereto duly completed and signed and upon payment in cash or by check of the aggregate Exercise Price for the number of shares for which this Warrant is being exercised determined in accordance with the provisions hereof. The Exercise Price and the number of shares purchasable hereunder are subject to further adjustment as provided in Section 4 of this Warrant.

 

This Warrant is subject to the following terms and conditions:

 

1.             Exercise; Issuance of Certificates; Payment for Shares.

 

(a)            Unless an election is made pursuant to clause (b) of this Section 1, this Warrant shall be exercisable at the option of Holder, at any time or from time to time, on or before the Expiration Date for all or any portion of the shares of Common Stock (but not for a fraction of a share) which may be purchased hereunder for the Exercise Price multiplied by the number of shares to be purchased. Company agrees that the shares of Common Stock purchased under this Warrant shall be and are deemed to be issued to Holder as the record owner of such shares as of the close of business on the date on which the form of subscription shall have been delivered and payment made for such shares. Subject to the provisions of Section 2, certificates for the shares of Common Stock so purchased, together with any other securities or property to which Holder is entitled upon such exercise, shall be delivered to Holder by Company at Company’s expense within a reasonable time after the rights represented by this Warrant have been so exercised. Except as provided in clause (b) of this Section 1, in case of a purchase of less than all the shares which may be purchased under this Warrant, Company shall cancel this Warrant and execute and deliver a new Warrant or Warrants of like tenor for the balance of the shares purchasable under this Warrant surrendered upon such purchase to Holder within a reasonable time. Each stock certificate so delivered shall be in such denominations of Common Stock as may be requested by Holder and shall be registered in the name of such Holder or such other name as shall be designated by such Holder, subject to the limitations contained in Section 2.

 

(b)            Holder, in lieu of exercising this Warrant by the cash payment of the Exercise Price pursuant to clause (a) of this Section 1, may elect, at any time on or before the Expiration Date, to surrender this Warrant and receive that number of shares of Common Stock computed using the following formula:

 

 

Where: X = the number of shares of Common Stock to be issued to Holder.

 

  Y= the number of shares of Common Stock that Holder would otherwise have been entitled to purchase hereunder pursuant to Section 1(a) (or such lesser number of shares as Holder may designate in the case of a partial exercise of this Warrant).

 

2 

 

 

  A= the price per share of the Common Stock as of the last Trading Day immediately prior to the date of exercise under this Section 1(b).

 

  B= the Exercise Price then in effect.

 

Election to exercise under this Section 1(b) may be made by delivering a signed form of subscription to Company via facsimile, to be followed by delivery of this Warrant. Notwithstanding anything to the contrary contained in this Warrant, if as of the close of business on the last business day preceding the Expiration Date this Warrant remains unexercised as to all or a portion of the shares of Common Stock purchasable hereunder, then effective as 9:00 a.m.  (Pacific time) on the Expiration Date, Holder shall be deemed, automatically and without need for notice to Company, to have elected to exercise this Warrant in full pursuant to the provisions of this Section 1(b), and upon surrender of this Warrant shall be entitled to receive that number of shares of Common Stock computed using the above formula, provided that the application of such formula as of the Expiration Date yields a positive number for “X”.

 

2.             Limitation on Transfer.

 

(a)            This Warrant and the Common Stock issuable hereunder shall not be transferable except upon the conditions specified in this Section 2, which conditions are intended to ensure compliance with the provisions of the Securities Act of 1933, as amended (the “Securities Act”). Each holder of this Warrant or the Common Stock issuable hereunder will cause any proposed transferee of the Warrant or Common Stock to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Section 2. Notwithstanding the foregoing and any other provision of this Section 2 but subject to the last sentence of Section 2(c), Holder may freely transfer all or part of this Warrant or the shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the shares, if any) at any time to any affiliate of Lender under the Loan Agreement, by giving Company notice of the portion of the Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant to Company for reissuance to the transferees(s) (and Holder, if applicable).

 

(b)            Each certificate representing (i) this Warrant and (ii) the Common Stock issued upon exercise hereof or upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall (unless otherwise permitted by the provisions of this Section 2 or unless such securities have been registered under the Securities Act or sold under Rule 144) be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legend required under applicable state securities laws):

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OPINION OF COUNSEL IN A FORM REASONABLY ACCEPTABLE TO COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED DUE TO AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR (C) CYTOSORBENTS CORPORATION OTHERWISE SATISFIES ITSELF THAT SUCH TRANSACTION IS COMPLIANT WITH SUCH LAWS.

 

(c)            Holder of this Warrant and each person to whom this Warrant is subsequently transferred represents and warrants to Company and agrees (by acceptance of such transfer) that it will not transfer this Warrant (or securities issuable upon exercise hereof unless a registration statement under the Securities Act was in effect with respect to such securities at the time of issuance thereof) unless (i) there is an effective registration statement under the Securities Act and applicable state securities laws covering any such transaction, (ii) pursuant to Rule 144 under the Securities Act (or any other rule under the Securities Act relating to the disposition of securities), (iii) Company receives an opinion of counsel, reasonably satisfactory to Company, that an exemption from such registration is available or (iv) the Company otherwise satisfies itself that such transaction is exempt from registration. Notwithstanding the foregoing or any other provision of this Section 2, Holder shall not transfer this Warrant (or securities issuable upon exercise hereof, or securities issuable, directly or indirectly, upon conversion of such securities, if any) to any competitor of Company, as determined in good faith by the Board, without the prior written consent of Company.

 

3 

 

 

(d)            As a condition to the exercise of this Warrant and the issuance of Common Stock, if requested by the Company by reasonable notice to Holder, Holder shall agree in writing to be fully bound by any investors rights, shareholder or similar agreements applicable to holders of Common Stock (“Investor Agreements”), provided that Holder shall not be required to agree to any terms of such agreements that are inconsistent with the terms of this Warrant.

 

3.             Shares to be Fully Paid; Reservation of Shares. Company covenants and agrees that all shares of Common Stock which may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all preemptive rights of any stockholder and free of all taxes, liens and charges with respect to the issue thereof. Company further covenants and agrees that during the period within which the rights represented by this Warrant may be exercised, Company will at all times have authorized and reserved, for the purpose of issue or transfer upon exercise of the subscription rights evidenced by this Warrant, a sufficient number of shares of authorized but unissued Common Stock, or other securities and property, when and as required to provide for the exercise of the rights represented by this Warrant. Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any domestic securities exchange upon which the Common Stock may be listed. Company will not take any action which would result in any adjustment of the Exercise Price (as described in Section 4 hereof) (i) if the total number of shares of Common Stock issuable after such action upon exercise of all outstanding warrants, together with all shares of Common Stock then outstanding and all shares of Common Stock then issuable upon exercise of all options and upon the conversion of all convertible securities then outstanding, would exceed the total number of shares of Common Stock then authorized by Company’s Certificate of Incorporation (as amended from time to time, the “Charter”), (ii) if the total number of shares of Common Stock issuable after such action upon the conversion of all such shares of Common Stock together with all shares of Common Stock then outstanding and then issuable upon exercise of all options and upon the conversion of all convertible securities then outstanding would exceed the total number of shares of Common Stock then authorized by Company’s Charter or (iii) if the par value per share of the Common Stock would exceed the Exercise Price.

 

4.             Adjustment of Exercise Price and Number of Shares. The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this Section 4.

 

4.1            Subdivision or Combination of Stock. In case Company shall at any time subdivide its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the outstanding shares of Common Stock of Company shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased. In each case, the number of shares of Common Stock for which this Warrant is exercisable shall be subject to appropriate adjustment.

 

4.2            Dividends. If at any time or from time to time the holders of Common Stock (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive,

 

(a)            Common Stock, or any shares of stock or other securities whether or not such securities are at any time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,

 

(b)            any cash paid or payable including as a cash dividend, or

 

4 

 

 

(c)            Common Stock or other or additional stock or other securities or property (including cash) by way of spin off, split-up, reclassification, combination of shares or similar corporate rearrangement, (other than shares of Common Stock issued as a stock split, adjustments in respect of which shall be covered by the terms of Section 4.1 above),

 

then and in each such case, Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to in clauses (b) and (c) above) which such Holder would hold on the date of such exercise had it been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares and/or all other additional stock and other securities and property.

 

4.3            Change of Control. In the event of a Change of Control (as hereinafter defined), this Warrant shall be automatically exchanged for a number of shares of Company’s securities, such number of shares being equal to the maximum number of shares issuable pursuant to the terms hereof (after taking into account all adjustments described herein) had Holder elected to exercise this Warrant immediately prior to the closing of such Change of Control and purchased all such shares pursuant to the cash exercise provision set forth in Section 1(a) hereof (as opposed to the cashless exercise provision set forth in Section 1(b)).  Company acknowledges and agrees that Holder shall not be required to make any payment (cash or otherwise) for such shares as further consideration for their issuance pursuant to the terms of the preceding sentence. “Change of Control” shall mean any sale, license, or other disposition of all or substantially all of the assets of Company, any reorganization, consolidation, merger or other transaction involving Company where the holders of Company’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction; provided that an issuance of equity securities for the primary purpose of raising capital shall not be considered a Change of Control under this Warrant. This Warrant shall terminate upon Holder’s receipt of the number of shares of Company’s equity securities described in this Section 4.3.

 

4.4            Sale or Issuance Below Purchase Price; “Pay-to-Play” Exemption.

 

(a)            The other antidilution rights applicable to the shares of Common Stock purchasable hereunder, if any, are set forth in Company’s Charter. Such antidilution rights shall not be restated, amended, modified or waived in any manner without Holder’s prior written consent if the effect of such restatement, amendment, modification or waiver on Holder would be more adverse to Holder with respect to the shares of Common Stock issuable upon the exercise of this Warrant than, and substantially dissimilar to, its effect on the other holders of the same class or series of Company’s Common Stock. Company shall promptly provide Holder with any restatement, amendment, modification or waiver of the Charter with respect to any such antidilution rights promptly after the same has been made.

 

(b)            In the event that Company’s Charter provides, or is amended to so provide, for the amendment or modification of the rights, preferences or privileges of the shares of Common Stock issuable upon the exercise of this Warrant, or the reclassification, conversion or exchange of the outstanding shares of such Common Stock, in the event that a holder of shares thereof fails to participate in an equity financing or debt financing transaction (as applicable, a “Pay-to-Play Provision”), and in the event that such Pay-to-Play Provision becomes operative in a transaction occurring after the date hereof, this Warrant shall automatically and without any action required become exercisable for that type of shares of equity securities as would have been issued or exchanged, or would have remained outstanding, in respect of the shares of Common Stock issuable hereunder had this Warrant been exercised in full prior to such event (and for that number of shares of equity securities as would have been issued or exchanged, or would have remained outstanding, in respect of the shares of Common Stock issuable hereunder had this Warrant been exercised in full prior to such event, if applicable), and had Holder participated in the equity or debt financing to the maximum extent permitted.

 

5 

 

 

4.5            Notice of Adjustment. Upon any adjustment of the Exercise Price, and/or any increase or decrease in the number of shares purchasable upon the exercise of this Warrant, Company shall give written notice thereof to Holder pursuant to Section 12. The notice, which may be substantially in the form of Exhibit “A” attached hereto, shall be signed by Company’s chief financial officer and shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.

 

4.6            Other Notices. If at any time:

 

(a)            Company shall declare any cash dividend upon its Common Stock;

 

(b)            Company shall declare any dividend upon its Common Stock payable in stock or make any special dividend or other distribution to the holders of its Common Stock;

 

(c)            Company shall offer for subscription pro rata to the holders of its Common Stock any additional shares of stock of any class or other rights;

 

(d)            there shall be any capital reorganization or reclassification of the capital stock of Company, or consolidation or merger of Company with, or sale of all or substantially all of its assets to, another entity;

 

(e)            there shall be a voluntary or involuntary dissolution, liquidation or winding-up of Company; or

 

(f)             Company shall take or propose to take any other action, notice of which is actually provided to holders of the Common Stock;

 

then, in any one or more of said cases, Company shall give Holder, pursuant to Section 12, (i) at least 20 days’ prior written notice of the date on which the books of Company shall close or a record shall be taken for such dividend, distribution or subscription rights or for determining rights to vote in respect of any such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action and (ii) in the case of any such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action, at least 20 days’ written notice of the date when the same shall take place. Any notice given in accordance with the foregoing clause (i) shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common Stock shall be entitled thereto. Any notice given in accordance with the foregoing clause (ii) shall also specify the date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action as the case may be.

 

4.7            Certain Events. If any change in the outstanding Common Stock of Company or any other event occurs as to which the other provisions of this Section 4 are not strictly applicable or if strictly applicable would not fairly effect the adjustments to this Warrant in accordance with the essential intent and principles of such provisions, then the Board shall make in good faith an adjustment in the number and class of shares issuable under this Warrant, the Exercise Price and/or the application of such provisions, in accordance with such essential intent and principles, so as to protect such purchase rights as aforesaid. The adjustment shall be such as will give Holder of this Warrant upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as Holder would have owned had this Warrant been exercised prior to the event and had Holder continued to hold such shares until after the event requiring adjustment.

 

5.             Issue Tax. The issuance of certificates for shares of Common Stock upon the exercise of this Warrant shall be made without charge to Holder of this Warrant for any issue tax in respect thereof; provided, however, that Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of the then Holder of this Warrant being exercised.

 

6 

 

 

6.             Closing of Books. Company will at no time close its transfer books against the transfer of this Warrant or of any shares of Warrant Stock issued or issuable upon the exercise of this Warrant in any manner which interferes with the timely exercise of this Warrant.

 

7.             No Voting Rights; Limitation of Liability. Nothing contained in this Warrant shall be construed as conferring upon Holder hereof the right to vote or to consent as a stockholder in respect of meetings of stockholders for the election of directors of Company or any other matters or any rights whatsoever as a stockholder of Company. No dividends or interest shall be payable in respect of this Warrant or the interest represented hereby or the shares purchasable hereunder until, and only to the extent that, this Warrant shall have been exercised; provided, however, that if any dividends are due or paid at any time on the underlying securities for which this Warrant is exercisable, then upon exercise, the securities issued to Holder shall be deemed to have accrued dividends and be paid identical dividends from the same time as the outstanding shares for which this Warrant is exercisable were first issued (or, if later, the date of this Warrant). No provisions hereof, in the absence of affirmative action by Holder to purchase shares of Common Stock, and no mere enumeration herein of the rights or privileges of Holder hereof, shall give rise to any liability of such Holder for the Exercise Price or as a stockholder of Company, whether such liability is asserted by Company or by its creditors.

 

8.             Amendment of Charter. Unless Holder consents thereto in writing, Company shall not amend its Charter prior to the exercise of this Warrant if the Common Stock would be adversely affected by such amendment in a manner that would be more adverse to Holder with respect to the shares of Common Stock issuable upon the exercise of this Warrant than, and substantially dissimilar to, such amendment’s effect on the other holders of the same class or series of Common Stock.

 

9.             Reserved.

 

10.           Rights and Obligations Survive Exercise of Warrant. The rights and obligations of Company, of Holder of this Warrant and of the holder of shares of Common Stock issued upon exercise of this Warrant, contained in Sections 6 and 8 shall survive the exercise of this Warrant.

 

11.           Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought.

 

12.           Notices. Any notice, request or other document required or permitted to be given or delivered to Holder or Company shall be deemed to have been given (i) upon receipt if delivered personally or by courier (ii) upon confirmation of receipt if by telecopy or (iii) three business days after deposit in the US mail, with postage prepaid and certified or registered, to each such Holder at its address as shown on the books of Company or to Company at the address indicated therefor in the opening paragraphs of this Warrant (or at such other location as Company may advise Holder in writing).

 

13.           Survival of Certain Obligations. All of the obligations of Company relating to the Common Stock issuable upon the exercise of this Warrant shall survive the exercise and termination of this Warrant. All of the covenants and agreements of Company shall inure to the benefit of and be binding upon the successors and permitted assigns of Holder. Company will, at the time of the exercise of this Warrant, in whole or in part, upon request of Holder but at Company’s expense, acknowledge in writing its continuing obligation to Holder in respect of any rights (including, without limitation, any right to registration of the shares of Common Stock) to which Holder shall continue to be entitled after such exercise in accordance with this Warrant; provided, that the failure of Holder to make any such request shall not affect the continuing obligation of Company to Holder in respect of such rights.

 

7 

 

 

14.           Descriptive Headings and Governing Law. The descriptive headings of the several sections and paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of Delaware.

 

15.           Lost Warrants or Stock Certificates. Company agrees that upon receipt of evidence reasonably satisfactory to Company of the loss, theft, destruction, or mutilation of any Warrant or stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, Company at its expense will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate.

 

16.           Fractional Shares. No fractional shares shall be issued upon exercise of this Warrant. Company shall, in lieu of issuing any fractional share, pay the holder entitled to such fraction a sum in cash equal to such fraction multiplied by the then effective Exercise Price.

 

17.           Representations of Holder. With respect to this Warrant, Holder represents and warrants to Company as follows:

 

17.1          Experience. It is experienced in evaluating and investing in companies engaged in businesses similar to that of Company; it understands that investment in this Warrant involves substantial risks; it has made detailed inquiries concerning Company, its business and services, its officers and its personnel; the officers of Company have made available to Holder any and all written information it has requested; the officers of Company have answered to Holder’s satisfaction all inquiries made by it; in making this investment it has relied upon information made available to it by Company; and it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of investment in Company and it is able to bear the economic risk of that investment.

 

17.2          Investment. It is acquiring this Warrant for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof. It understands that this Warrant, the shares of Common Stock issuable upon exercise thereof and the shares of Common Stock issuable upon conversion of the Common Stock, have not been registered under the Securities Act, nor qualified under applicable state securities laws.

 

17.3          Rule 144. It acknowledges that this Warrant and the Common Stock issuable upon exercise of this Warrant must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. It has been advised or is aware of the provisions of Rule 144 promulgated under the Securities Act.

 

17.4          Access to Data. It has had an opportunity to discuss Company’s business, management and financial affairs with Company’s management and has had the opportunity to inspect Company’s facilities.

 

17.5          Accredited Investor. It is an “accredited investor” within the meaning of Regulation D promulgated under the Securities Act.

 

18.           Additional Representations and Covenants of Company. Company hereby represents, warrants and agrees as follows:

 

18.1          Corporate Power. Company has all requisite corporate power and corporate authority to issue this Warrant and to carry out and perform its obligations hereunder.

 

8 

 

 

18.2          Authorization. All corporate action on the part of Company, its directors and stockholders necessary for the authorization, execution, delivery and performance by Company of this Warrant has been taken. This Warrant is a valid and binding obligation of Company, enforceable in accordance with its terms.

 

18.3          Offering. Subject in part to the truth and accuracy of Holder’s representations set forth in Section 17 hereof, the offer, issuance and sale of this Warrant is, and the issuance of Common Stock upon exercise of this Warrant, will be exempt from the registration requirements of the Securities Act, and are exempt from the qualification requirements of any applicable state securities laws; and neither Company nor anyone acting on its behalf will take any action hereafter that would cause the loss of such exemptions.

 

18.4          Listing; Stock Issuance. Company shall secure and maintain the listing of the Common Stock issuable upon exercise of this Warrant upon each securities exchange or over-the-counter market upon which securities of the same class or series issued by Company are listed, if any. Upon exercise of this Warrant, Company will use commercially reasonable efforts to cause stock certificates representing the shares of Common Stock purchased pursuant to the exercise to be issued in the names of Holder, its nominees or assignees, as appropriate at the time of such exercise.

 

18.5          Charter Documents. Company has provided Holder with true and complete copies of Company’s Charter, By-Laws, and each Certificate of Designation or other charter document setting, forth any rights, preferences and privileges of Company’s capital stock, each as amended and in effect on the date of issuance of this Warrant.

 

18.6          Reserved.

 

18.7          Financial and Other Reports. Until the earlier of (a) the Expiration Date, (b) the termination of this Warrant pursuant to Section 4.3, and (c) the exercise of this Warrant pursuant to Section 1, Company shall furnish to Holder (i) promptly following delivery to the Board after the close of each fiscal year of Company, a balance sheet, together with an income statement, a cash flow statement and a statement of changes in equity, for such fiscal year, in substantially the same form as such annual financial statements are furnished to the Board; (ii) within 60 days after the close of each fiscal quarter of Company, an unaudited balance sheet, income statement and cash flow statement, each at and as of the end of such quarter. In addition, until the earlier of (a) the Expiration Date, (b) the termination of this Warrant pursuant to Section 4.3, and (c) the exercise of this Warrant pursuant to Section 1, Company agrees to provide Holder at any time and from time to time with such information as Holder may reasonably request for purposes of Holder’s compliance (as determined by Holder in its reasonable discretion) with regulatory, accounting and reporting requirements applicable to Holder (e.g., Fair Value Accounting Standard 157), including any 409A valuation reports (or equivalent reports) and budgets, as well as information with respect to whether the securities issuable upon the exercise hereof constitute “qualified small business stock” for purposes of Section 1202(c) of the Internal Revenue Code and Section 18152.5 of the California Revenue and Taxation Code. Notwithstanding the foregoing, Company shall not be required to furnish to Holder the financial information described in this Section 18.7 in the event such financial information has been previously delivered to Lender pursuant to the Loan Agreement. For avoidance of doubt, any information provided hereunder (including, without limitation, under this Section 18.7) that constitutes confidential information under the Loan Agreement shall be subject to the confidentiality provisions thereof.

 

19.           Compliance with Insider Trading and Public Disclosure Law. Holder acknowledges that it may become aware of material, non-public information concerning the Company hereunder or under the Loan Document. Accordingly, Holder covenants and agrees not to, at any time while in possession of material non-public information concerning the Company: (i) effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate in, or in any way assist any other person to effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate in, any trading of any securities (or beneficial ownership thereof) of the Company, (ii) disclose or “tip” material, non-public information concerning the Company to any person or entity, or (iii) give trading advice of any kind to any person or entity concerning the Company. This Section 19 shall survive termination of this Warrant.

 

9 

 

 

20.           Counterparts; Facsimile. Holder’s execution and delivery of Holder’s counterpart signature page to this Warrant via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) shall constitute Holder’s effective execution and delivery of this Warrant and agreement to and acceptance of the terms hereof for all purposes.

 

[Remainder of this page intentionally left blank; signature page follows]

 

10 

 

 

[Signature Page to Warrant]

 

IN WITNESS WHEREOF, Company has caused this Warrant to be duly executed by its officer, thereunto duly authorized as of the date of issuance set forth on the first page hereof.

 

CYTOSORBENTS CORPORATION  
   
By:    
Name: Phillip P. Chan, MD, Ph.D.  
Title: Chief Executive Officer  
   
AGREED AND ACCEPTED:  
   
HOLDER:  
   
AVENUE VENTURE OPPORTUNITIES FUND, LP  
   
By: Avenue Venture Opportunities Partners, LLC  
Its: General Partner  
   
By:    
Name: Sonia Gardner  
Title: Authorized Signatory  

 

 

 

 

FORM OF SUBSCRIPTION

 

(To be signed only upon exercise of Warrant)

 

To:        ____________________________

 

¨The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to purchase thereunder, (1) ________________ (_____) shares1 (the “Shares”) of Stock of __________ and herewith makes payment of _____________ Dollars ($________) therefor, and requests that the certificates for such shares be issued in the name of, and delivered to, _________, whose address is ___________.

 

¨The undersigned hereby elects to convert ______ percent (__%) of the value of the Warrant pursuant to the provisions of Section 1(b) of the Warrant.

 

The undersigned acknowledges that it has reviewed the representations and warranties contained in Section 17 of this Warrant and by its signature below hereby makes such representations and warranties to Company.

 

  Dated   
     
  Holder:  
     
  By:   
     
  Its:  
     
  (Address)  
     
     
     
     

 

 

1 Insert here the number of shares called for on the face of the Warrant (or, in the case of a partial exercise, the portion thereof as to which the Warrant is being exercised), in either case without making any adjustment for additional Common Stock or any other stock or other securities or property or cash which, pursuant to the adjustment provisions of the Warrant, may be issuable upon exercise.

 

 

 

 

ASSIGNMENT

 

FOR VALUE RECEIVED, the undersigned, the holder of the within Warrant, hereby sells, assigns and transfers all of the rights of the undersigned under the within Warrant, with respect to the number of shares of Common Stock covered thereby set forth herein below, unto:

 

Name of Assignee  Address  No. of Shares
       
       
       

 

  Dated   
     
  Holder:  
     
  By:   
     
  Its:  

 

 

 

 

EXHIBIT “A”

 

[On letterhead of Company]

 

Reference is hereby made to that certain Warrant dated June 28, 2024 issued by CYTOSORBENTS CORPORATION, a Delaware corporation (the “Company”), to [AVENUE VENTURE OPPORTUNITIES FUND, LP], a Delaware limited partnership (the “Holder”).

 

[IF APPLICABLE] The Warrant provides that the actual number and type of shares of Company's capital stock issuable upon exercise of the Warrant and the initial exercise price per share are to be determined by reference to one or more events or conditions subsequent to the issuance of the Warrant. Such events or conditions have now occurred or lapsed, and Company wishes to confirm the actual number of shares issuable and the initial exercise price. The provisions of this Supplement to Warrant are incorporated into the Warrant by this reference, and shall control the interpretation and exercise of the Warrant.

 

[IF APPLICABLE] Notice is hereby given pursuant to Section 4.5 of the Warrant that the following adjustment(s) have been made to the Warrant: [describe adjustments, setting forth details regarding method of calculation and facts upon which calculation is based].

 

This certifies that Holder is entitled to purchase from Company __________________________, at the Holder’s option, either (i) (____________) fully paid and nonassessable shares of Company’s _________ Stock at a price of _________________________ Dollars ($__________) per share or (ii) (____________) fully paid and nonassessable shares of Company’s _________ Stock at a price of _________________________ Dollars ($__________) per share. The applicable Exercise Price and the number of shares purchasable under the Warrant remain subject to adjustment as provided in Section 4 of the Warrant.

 

Executed this ___ day of ________________, 20___.

 

  CYTOSORBENTS CORPORATION
   
  By:  
   
  Name:  
   
  Title:                      

 

 

 

EX-99.1 5 tm2418904d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

CytoSorbents Secures $20 Million Credit Facility

 

Credit facility provides timely non-dilutive capital to support ongoing global commercialization of CytoSorb® as well as regulatory submissions and potential commercialization plans for DrugSorb™-ATR in the U.S. and Canada

 

PRINCETON, N.J., July 2, 2024 -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company entered into a new $20 million credit facility with Avenue Capital Group, including its Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.. Armentum Partners, LLC served as financial advisor to the Company on the transaction. Proceeds from the facility are intended to provide non-dilutive working capital to support the Company’s ongoing global CytoSorb® franchise in critical care and cardiac surgery that generated $32.2 million in trailing 12-month sales as of March 31, 2024, planned marketing applications to U.S. Food and Drug Administration (FDA) and Health Canada for DrugSorb™-ATR and initial launch and commercialization preparations if approved, and refinancing of existing Bridge Bank debt.

 

The credit agreement, which has an initial term of three years, provides up to $20 million in total term loan capital including an initial tranche of $15 million, with immediate availability of $10 million and an additional $5 million with the timely acceptance by U.S. FDA of the Company’s planned De Novo application for DrugSorb-ATR and certain liquidity requirements. A second tranche of $5 million would be available in the second half of 2025 with FDA marketing clearance for DrugSorb-ATM to help support an anticipated launch of the therapy in the United States.

 

Ms. Kathleen Bloch, Chief Financial Officer of CytoSorbents stated, “We are pleased to enter into this relationship with Avenue Capital Group to strengthen our financial position, expand our working capital, and to enable us to confidently pursue our regulatory and commercialization objectives. We believe the planned marketing applications of DrugSorb-ATR to U.S. FDA and Health Canada this summer and the prospects of opening an estimated total addressable market in the U.S. and Canada in excess of $0.5 billion if approved, represents a potential watershed event for the Company. As an FDA Breakthrough Device, DrugSorb-ATR aims to reduce serious bleeding complications in patients undergoing coronary artery bypass graft (CABG) surgery on the blockbuster blood-thinning drug Brilinta® (ticagrelor, AstraZeneca) – a major unmet medical need. The full $20 million is expected to help fund the Company through both Health Canada and U.S. FDA regulatory decisions.”

 

 

 

 

Mr. Chad Norman, Senior Portfolio Manager at Avenue Capital Group stated “We have followed the CytoSorbents story for many years and all of the exciting work the company is doing to help save lives in critical care and cardiac surgery. We are pleased to now partner with CytoSorbents to support the international growth of CytoSorb® and other products, and importantly help fund the U.S. and Canadian initiatives with DrugSorb-ATR. Many of us unfortunately know family, friends, and colleagues on blood thinners and the high bleeding risk they have, should they need surgery. We see a great opportunity to be part of a solution to address this major problem.”

 

About Avenue Capital Group

 

Avenue Capital Group is a global investment firm, founded in 1995, that is primarily focused on specialty lending, opportunistic credit, and other special situations in the United States, Europe, and Asia. The Senior Principals and the Senior Portfolio Managers have spent virtually their entire careers investing in the private and public debt markets. Headquartered in New York, with three offices across Europe, four offices throughout Asia, an office in Silicon Valley, and an office in Abu Dhabi, the firm manages assets estimated to be approximately $12.5 billion. Avenue draws on the skills and experience of over 185 employees worldwide and maintains a well-developed infrastructure with experienced accounting, tax, compliance, risk management, legal, investor relations, and information technology professionals. Avenue’s team of over 60 investment professionals has deployed approximately $100 billion in investments across a variety of industries, regions, and market cycles with an eye toward value creation and capital conservation. Through rigorous due diligence and a robust network of relationships, the Firm proactively identifies public and private opportunities in fragmented, capital-constrained markets.

 

About CytoSorbents Corporation (NASDAQ: CTSO)

 

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. As of March 31, 2024, more than 237,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.

 

 

 

 

The DrugSorb™-ATR antithrombotic removal system, an investigational device based on the same polymer technology as CytoSorb, has received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The Company has completed the FDA-approved, randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 140 patients at approximately 30 centers in U.S. and Canada to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. This pivotal study is intended to support U.S. FDA and Health Canada marketing approval for DrugSorb-ATR in this application.

 

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $50 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others.  For more information, please visit the Company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and  X

 

 

 

 

Forward-Looking Statements

 

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, statements about potential exposures resulting from our cash positions, representations and contentions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

 

Please Click to Follow Us on Facebook and X

 

U.S. Company Contact:
Kathleen Bloch, CFO
305 College Road East
Princeton, NJ 08540
+1 (732) 398-5429
kbloch@cytosorbents.com

 

Investor Relations Contact:
Eric Ribner
LifeSci Advisors, LLC
250 W 55th St, #3401
New York, NY 10019
+1 (646) 751-4363
ir@cytosorbents.com

 

 

 

GRAPHIC 6 tm2418904d1_ex10-3img001.jpg GRAPHIC begin 644 tm2418904d1_ex10-3img001.jpg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end GRAPHIC 7 tm2418904d1_ex99-1img001.jpg GRAPHIC begin 644 tm2418904d1_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBBD 4444 %%%% !1110 44 M44 %%%% !1110 4444 %7#./R8D5F:=:-J&IVEDN=UQ,D0QZL MP']:[GXE>"M.\+6^G3Z9YVR8O'+YK[B2 ""./][/X5WOV<6H6W U/"OQ>N1< M1VOB)4DB8X^V1IM9/=E'!'T ^AKV)65U#*P96&00<@BOD>O:=%\;S:#\+-+U M%[)KTQS&S8&79M W;3G!X %@M'! >H45Y'_PO ?]"\?_ -_^UUZ5HFL M)K'A^UU8Q^0D\7F%"V[9Z\\9Z5RSI3@KR0&E17D?_"\!_P!"\?\ P-_^UUNZ M%\4;?5-/U/4+S3'L[33UC,CI-YI)=MJC&T53H5$KM :]W\1?"EC>3VEQJNR> M"1HI%^SRG:RG!&0N#R*+3XB^%+Z\@M+?5=\\\BQ1K]GE&YF. ,E<#DU\_:[> M1:AXAU.]@),-Q=RRQ[A@[61:?XATR]G)$-O=Q2R;1D[5<$X_ 5U M?58\M]0/JFBLW0M=LO$6FKJ%@7,!8H"Z[3D=>*YGQ1\3])\.W3V4,3W]Y&<2 M)&X5$/H6YY]@#[XKB4)-\J6H'<45XN?C9J.3C1[4#MF1JW-$^,FFW8F?4C ('YUH\/42O8#TRN/\8>-D\/L+*S19K]AEM_W8@>A/J?;_)Z MV*6.>%)89%DC.6DU6X3)SB%O+ _[YQ3+?Q7K]L^Z/5[LG(/[R0R# M\FS47A[34U?7[.PD8K'*^'*G!V@$G'X"M'QMH5IX?UR.VLR_DR0++ASD@DL, M9_X#G\:]/]VI>SM^!P^^X\]SK?"OQ$:^NXK#5T19)#MCN$& 6[!AVSZC\N]> MA5\VJS(ZNA*LIR".H-?1UO*+BVBF P)$#8],C->?BZ,8-./4[,/472'#HC;50^A;GGV -Y.-,M\?\ 71JQAAJLE=(T ME7A%V;/4J*\\L/BI;22JE_ISPJ< R1/OQ[[2!Q^)KO+.\MK^U2YM)DFA<95T M.0:BI2G3^)%PJ1G\+)Z*XC7_ (A#0];N--_LOS_)V_O//VYRH;IM/K5"+XJ& M:9(DT7YG8*,W7<_\ JUAJK5TB'6@G9L]&KSOQ[XHUC1-=@MM/NQ#$ULLA7RT M;YBS#.2#V J]XC^(EMI-V]G8P"[FC.)'+X13W''4_P JYGXI?\C-;?\ 7FO_ M *&];8:BU-OGJO3#\0[31]#TVRL[?[7CT5YG:_%:3SP+S3%\D]3#)\P_ ]?TKT2QO;?4;**\M9!)!* MNY&%>?4HSI_$CLA4C/X66**PO$'BS3/#JA;EVDN6&5@C&6(]3V _SS7&2_%: MY,A\G2H53L'E)/Y@"JAAZDU=(4JT(NS9ZA17G%C\54:0+J&FE$)_UD#YQ_P$ M_P"-=[I^H6FJ6:75E.LT+]&4]#Z$=C[5-2C.G\2'"I&?PLM45RWBKQD/#%U; MP_8/M/G(7SYVS&#C^Z:Y_P#X6R/^@*?_ *_^PJHX>I)FG:YZ97.R>._#<4KQOJ6'1BK#R)."/^ UFVNAQZP MTK/9R8VLBY//'2O"+R59KV>5,[7D9AGT)K3#X=5+\Q%:MR6Y3V^S\9^'[^\B MM+6_\R>5MJ+Y,@R?J5Q6]7S_ .'KZ'3?$%E>7!80PR;FVC)Q7M]AK=CJ&D?V MI%+LM &)>4;< '!S^5+$8?V;7+L.C5YT[FC17GNI?%.VBD:/3;%YP./-E;8/ MP&"3^E9X^*U[N&[3+S$_]]FOJ:OE?7_\ D9-4_P"ON7_T,UVX3=@3>%/^1PT3 M_K_@_P#1BUZC\;/^0/I?_7PW_H->7>%/^1PT3_K_ (/_ $8M?1/B+POIOBBW MAAU)962%BZ>6^WDC%:5Y*-2,F!\OUZ?H=JVI_ _6(MN6MKEI4(&CV2NMM=;]XD;?RRA3^& .*FIB(R2MW M^8J]S\!7Z'X27)=E"6<=RK8Z@8+\_@U>'RQO#*\4B[71BK#T(ZUZ1X%U$1?# M7Q?;,6(CB9@ .ADC*9_\='Y5M7C>*]4!YI7IO@#PW)X@\!>(;2%UADO)X8Q, M^2O[LA\8_']:\RKWWX16WD>!EDVL/M%S))D]\87(_P"^?THQ$G&%T!X9J=DV MF:K>6#N':VG>$L!PQ5B,_I1IEDVIZK9V".$:YG2$,1PI9@,_K5WQ7_R.&M_] M?\__ *,:CPI_R.&B?]?\'_HQ:UN^6_D![!+;7/PZ^%U[%]J22[4L(I(P1AI" M ",]QDG\*\))+$DDDGDD]Z][^+S[/ Y7'W[J,?3J?Z5X'6&&UBY/=L#K_#W@ MI=;\'ZQKKW;1&Q#^7&%R'*)O;/X$"N0KUWP%_P D>\3?]O7_ *3K7D5:TY-R MDGT8'LGP9UR>XM;W1IG9TM\309.=JDX9?IG!_$URGB.W-KXEU.$KMQ#_P#HR.NZ\=>#)=7?^U-.4&Z5,2Q=#*!T(]P/S&/Q MSA.-.NT]F<^(@Y1TZ'F.EZ@^E:I;7T:AF@D#[3_%ZBO36LO#GQ#N([TWEU%= M1Q"-K=7564 DYP5.>IY''2O*9(WBD:.1&1U.&5A@@^XI89I;>9)H9'CE0Y5T M."I]0:ZJE+G]Z+L^YPPJL_\*MT3_GZU#_OXG_Q%;7B:^.@^$;F6W@_"S4 M9$U"[TUG/E21^?5UWPW_P"1NC_ZXO\ RHQ"3I2N%%VJ M(K>/_P#D=M1_[9_^BUKG$=HW5T)5E.01V-='X_\ ^1VU'_MG_P"BUKFJJC_# MCZ$U/C?J*222222>I-=M\4O^1FMO^O-?_0WJ[I/PP:YL(Y]0OFAED4-Y4: [ M ?4GO_GFJ7Q2_P"1FMO^O-?_ $-ZQ56$ZR47M?\ 0UY)1IMOK8XBNFUGPHNE M>%M-U@71D:[V;XRN N]"PP?8#%H3WMP Q;58 @EE.?_ !VMJBDH-0WZ&4+.2YMC M(OK5K'4+FS=@S02M$6'2R\0BQ9_]'O%*E2> X!(/Z$?C7+ZG M=K?ZK>7BJ46XG>4*3R S$X_6KGA>4Q>*M+8 9-U&O/N:DT^PX/EFF MNYU7Q5_Y">G_ /7%O_0J\_KT#XJ_\A/3_P#KBW_H5>?U.&_A1*K_ ,1G3ZEX M3^P>#[+6Q<.TDY7?$5 "JP)!!_+\ZYBO4_$W_)*M-_ZXVW_H(KRRBA-SBV^[ M"K%1:2[(]%\,:5/XC^'EQIR3K&5O3L9QD *V./A55+DBQ^E:>^ MJZI;V*.L;3OM#,,@5VWBNQN/#G@6PT=IUDWW+-(R @,.6 _,C\JYGP?_ ,C= MIG_78?R-=W\4K5Y=%M+E5RL,Q#'T##^61_*E5F_;0B]ATX_NY2ZGE%=1K'A) M=+\)Z?K NFDDN=A>/;@*'4L.?; %!=['J MQ'!/XXS7/P_#OPU= MBJ\*B2CNCLH4I0;;+-%%%<)U!1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\K^(/^1DU M3_K[E_\ 0S7U17R_XMB:'QCK2,NW_3IB![%R1^A%=N$^)@-\*?\ (X:)_P!? M\'_HQ:]T\>^+[CPA8VD]O:Q7!GD*$2,1C SVKPCPU*D'BK1YI#A([V%F/H X M)KU'XVRH--TB(GYVFD8#V /\Q6M:*E5BF!E_P#"Z]1_Z!%K_P!_&KT+P-XG MG\6:'+J$]M';LEPT05"2" JG//\ O5\V5] ?"6(Q^!(6*E1)/(P./O%/\ D<-$_P"O^#_T8M'BO_D< M-;_Z_P"?_P!&-1X4_P"1PT3_ *_X/_1BUT?8^7Z >Q_&'_D24_Z^X_Y-7@M> M_?%U0W@9R>JW,9'ZC^M> UCA?X8'KO@+_DCWB;_MZ_\ 2=:\BKUSP%_R1[Q- M_P!O7_I.M>1U=+XI^H'HOP8_Y'"[_P"O!_\ T9'7J-SXZ\/V=W-;37;K+"[1 MN/)B7F@ M:@;.\5=V-R.IRKKZC\JL^$"!XNTPD@?OP.:ZOXL"/S]*(QYI64-SSC*X_K6T M;TJBIIW3.27[R#F]T>= E2""01R"*]4\77IU'X:VEXQR\WDL_'\6.?US7E5> MDZQ_R2*P_P"V?\S55U[T'YDTG[LEY'FU>E>#_P#DF6O_ /;Q_P"B5KS6O2?! MY'_"L]?&>?\ 2/\ T2M/$_ O5?F%#XODSS:NN^&__(W1_P#7%_Y5R-=A\-(V M?Q9N4<1V[LWTX'\R*NO_ I>A%+XT5/'_P#R.VH_]L__ $6MN5Y'\4O^1FM MO^O-?_0WKR\'_%^\]#$_PSB*]*\8?\DRT#_MW_\ 1+5YK7I7C#_DF6@?]N__ M *):O0K?'#U_0XZ7PR]#S6O2O!__ "3+7_\ MX_]$K7FM>F^"8FG^'.MQ)C< M[3J,^IA448KX%ZK\PH?%\F>95O>$O#\?B359;.2X: ) 9=RKG.&48_\ 'JP: M[?X6_P#(S7/_ %YM_P"AI6E:3C3;1%))S28^Y\(>&K.YDM[GQ,(YHSAD:,9! MJ?2/#WAF#6;&6W\2K-,DZ-'%Y>-[!A@?B:YKQD<^+]3_ .NW]!47A:(R^*M+ M4$#%RC?D<_TK'DDZ?,Y/;R[&G-%3LH]3J?BK_P A/3_^N+?^A5Y_7H'Q5_Y" M>G_]<6_]"KS^KPW\*)-?^(SU/Q/_ ,DJTW_KC;?^@BO+*]3\3_\ )*M-_P"N M-M_Z"*\LJ<+\+]657^)>B/6OA9_R+EU_U]M_Z E>7:C_ ,A.[_Z[/_Z$:]1^ M%G_(N77_ %]M_P"@)7EVH_\ (3N_^NS_ /H1J:/\:H.K_"@:?@__ )&[3/\ MKL/Y&O<;JU@O;62VN8EEAD7:Z,."*\.\'_\ (W:9_P!=A_(UZ)\1=3U#2]-L MYK"XD@W3%'9._&0/T-8XJ#G6C%&E"2C3;9R_B+X%N4?ZC^O6O< M=(U*+6-*MM0A!"3)NVDYVGH1^!!%?/->S?#)G ]N:QQM./+S]37" MS?-R]#K:***\H[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\1^+/A6YMM9;7K:%GM+ MD#SBB\1R 8R?8@ Y]^7_P ,O"M_*93IWV=R23]GD* _\!Z# M\ *I0?"+PO"^YUO)QNSMDGP,>GR@<5W?6J>[0'B6C:+?Z_J4=AI\)DF<\G^% M!W9CV%?3&@Z3%H6A6>F0G*V\84MC&YNK'\22?QI^EZ-INB6OV?3;.*VB[B-> M6/J3U)]S5ZN6M6]IHM@/+_C79A]%TN]XS#<-#U_OKG_VG7BU3SWMU= "XN9I M@#D>9(6Q^=,A@EN)/+AB>1^NU%)/Y"O0I0Y(\K8$VFVAO]5L[, DW$Z184X/ MS,!Q^=?5]>,?#;P!J UB#6M6MGMK>W^>&*48>1^QV]0!UY[X[5[/7%BIJ4DE MT ^;OB%I,^E>--1\V-ECN96N(G/1PYRRQC@MC&?T%0ZOXFC ^<-.\2:II>D7VEVEP$M;T;9EV D@C!P>V1Q64 68 D MG@ =Z^@)/A-X4>0LMM<(">%6X; _/)K;TCP;X>T*43:?ID,*@M4@,+X8^$Y_#FBRW-]'Y=]>E69#UC0?=4^AY)/U [5A_$CP_<0ZHVL M01,]M. )2H_U;@8Y]B .?6O5J1E5U*L RD8((R"*YH5Y1J^U&\U.?S[VYDGE VAI&S@>@]*]EO? 7AV]D,ALO(8 MGGR'*#\N@_ 55A^&OA^-@76YE&7'X< 5W_7*3U:U.+ZM4VN>3:9IEWJ]_ M'9V<1DE<_@H[DGL!7MM]X?2X\(-H<;#"VZQHQXRRX()Q[@$UH:?I=CI4'DV% MK% G?8.6^IZG\:MUQU\2ZDDUI8Z:5!03OU/G*ZM9[*ZDMKF)HIHVVNC#D&K= MEKFH:=IUW86TP2WNUVRKM!)&,'![9'%>Y:EH>F:PH%_913D# 8C# >@86*-* M6'Y7S2/$?'__ ".VH_\ ;/\ ]%K7-5[]>>&]&U"Z>ZN]/AEG?&YV!R<# _0" MH/\ A#_#W_0)M_R-:0QD(Q4;/0B6&DY-W-RO(_BE_P C-;?]>:_^AO7KE9U_ MH.E:I.L]]8Q3RJNP,XY R3C]37'0J*G/F9TU8.<;(^?:U]3U;5Y=.M=(U!G6 M"V"M'&Z;3C'RD^O!X]C7L'_"'^'O^@3;_D:LZIX>TK68D2^LXY-B[48?*RCT M!'./;I7:\;!M>ZV> ]+DT[PI$EQ%LDN&:9D8" M- TRX6XBL_,E4Y5IF+[3[#I^.*Z*L<3B547+$UHT'!W9X3XI\.7'A[5'C*$V MDC$V\O8KZ9]15'2-8O=#OOM=C($EVE#E<@J>Q'X#\J]_N+:"[A:&YACFB;JD MBA@?P-#/&KJZGO;J6 MZN9#)-*Q=W/L7$BV M E<=#.Q/TKH0 H X %16Q:E'E@AT\.U+FD>6_%7_D)Z?_ -<6_P#0 MJ\_KZ#U#1-,U61'OK.*=D&%+CH*I_P#"'^'O^@3;_D:='%QA!1:%4P\I2?2K"ZT]+">UC>UC"A8CT 7@?E6?\ \(?X>_Z! M-O\ D:5'%1IIIKJQU*$IM-,POA9_R+EU_P!?;?\ H"5Y_P"+-.GT[Q-?I-$4 M669Y8CV9&8D8_/%>W:?IEEI<#0V-ND$;-O*IT)QC/Z"EO=.LM2B$5[:PW"#H M)$#8^GI6<,2HU7.VC+E0YJ:C?5'SY:W4]C=Q75M(8YHF#HP[$5Z+ -2\<> + MHSNLU];W>8<*%W;57CC SAFKK/\ A#_#W_0)M_R-:5AIMGI<#06-ND$3-O*I MT)P!G]!6E7%1E9Q6J(IT)1NF]#YX='BD:.161U.&5A@@^A%:=SXCU.\T6#29 MKC=:0XVKM&<#H"?05[7J7A[2-7.Z^L(97Z>9C:__ 'T,']:QO^%<>'=^[R)\ M9SM\XX^GK6JQE.5G):D/#37PL\;AAEN)TAAC:25V"JBC))/85[UX9TIM%\.V M=C)CS44M)C^\22>>^,X_"I-,\/Z5H^386,4+$8+\LV/3<Y"+NV)P+B(D_[8J175QE&##.,@YKF(M&TI?&LL2Z99B-;".14$"X#> M8_S 8Z\#GVK%T>\N-(TV2* .SZJ\OV4CD+<"9HS]!M*-_P :LO9)KW7V+]H MUN>@JZN,HP89QD'-.KG?!MLEGI5W:QY*0WT\:YZX#X'\JZ*LIQY9-%Q=U<** M**DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH 9Y,0G,_E)YQ4(9-HW%0_\ /\__ M 'TU-.FWQ_Y?W_[Z:M:BE[-#]M+^D8QTO4/^@B__ 'VU-.DZD?\ F)/_ -]M M_C6W11[.(_;2\ON1@G1]3/\ S%)/^^V_QIIT75?^@M)_WVW^-=!12]E'^F/Z MQ/R^Y'.'0]6/_,7D_P"^W_QIIT'6#_S&9?\ OX_^-=+11[*/],?UB?E]R.7/ MA_63_P QN7_OX_\ C33X=UL]-7W+_(XH^%/$7_0R3_] M_9/\:8?"7B0_\S+/_P!_I/\ &NXHH]C'S^]C^N5/+[E_D<*?"/B7_H9Y_P#O M])_C3#X/\3_]#3*#_S-5Q_W^E_Q MIA\%>*C_ ,S97_@* M_P CS7_A!/%__0Y7/_?^;_&C_A!/%_\ T.5S_P!_YO\ &O2J*/8Q_IA]?K>7 M_@*_R/-?^$$\7_\ 0Y7/_?\ F_QH_P"$$\7_ /0Y7/\ W_F_QKTJBCV,?Z8? M7ZWE_P" K_(\U_X03Q?_ -#E<_\ ?^;_ !H_X03Q?_T.5S_W_F_QKTJBCV,? MZ8?7ZWE_X"O\CS7_ (03Q?\ ]#E<_P#?^;_&C_A!/%__ $.5S_W_ )O\:]*H MH]C'^F'U^MY?^ K_ "/-AX$\7_\ 0XW/_?\ E_QIP\#>+O\ H<+G_O\ R_XU MZ/11[&/]-A]?K>7_ ("O\CSH>"/%G_0W7/\ W_E_QIP\$^*Q_P S;QCY_>P^N5?+[E_D<2/"GB,?\S)/_ -_9/\:7W+_(Y(>&]='_ #'IO^_K_P"-.'AW7/\ H.R_]_'_ ,:ZNBCV M,?/[V+ZU4\ON7^1RP\/:T/\ F-R_]_'_ ,:>-!U@?\QJ7_OX_P#C7344_8Q_ MIL/K,_+[DRC_3%]8GY?RC_3%[>?E]R,4:5J/_01? M_OMJ<-,OQUU!_P#OIJV**?LXB]M+R^Y&4-.OA_R_/_WTU.%A>#_E];_OHUIT M4_9H7M9?TC.%E=C_ )>V_P"^C3Q:7(_Y>F_,U>HHY$+VDBF+6X'_ "\'\S3A M;S#K.?S-6J*?*A<[*XAE_P">I_,TX12?\]#^=344[(7,R,(W]ZG!3ZTZBBPK MB8-%+13$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110!EW/B"QL]>M='G,B75TNZ(E?D;KQN]>.GT]:37O$.G^'+2.YU&1E21 M]BA%W,3@GIZ<5@?$G3I9=%@UBTXO-*F6=&QD[GU!_ ^6:QE-IN*WZ'HT<-3G&-5OW5?F]5_G=?B>ER:A:QZ8VHM M*/LJP^?Y@Z;,9S^50:7K5GJVDKJENS):,&(>8;.%)!//;@_E7DW]MWT_A*+P M5AAJOVW[&PY_U0;/7Z\?05U/Q%B;1?AY;Z?8@K )(K=R!_ %)R?J5&?K[TE5 MNF^R_$IX)1E&FWK)Z>G?Y]"[<_$_P[!<-%$;NY1#AYH(C(?1@>13]'L++3=)MK;3T1;94!0H/OY'WCZD]UTU0EO=6NZYB3Y50[2KWMWTT-^ M^\>:-8:CJS!"@XYQ@EOH*UOA?&EQ;:MK/GQ&?4+G=+!&"!"06(' M/KO/X8]ZF-1N5O4UK86G"DYKM'K??RZ'5Z;KUCJM_J%G:LYFL)!'.&7 !)(X M]?NFF:3XCT_6[JZ@L#+*+5MLDNS$><] >_\ GVKR?4+[4[*X\:?8$802WRQW M4ROIC':G"HY.Q&( MPT*,.;>]K>6B;O\ ?HB:RU^QU#6+W2X&D-S9_P"M!7 'T/>H=/\ %6DZGK-U MI,$Y%[;,R-&Z[=Q4D-M/?&*YKPI_R4OQ1^'\Q7,V/A^ZUCQ#XKO--G:#5=/U M RVS@XSEY=R_C@=?3'0FE[26EN[+6$I7DI.UHQ=_-]_(]3UC7;+0X[=[UG N M)A"FQ<_,>E6KZ_M=,LY+N]G2"",99W/ _P#K^U>6:_XHC\2:'HWF(8-0MM3C MCNH&&"K8/('H<'Z1*P5 MG&,]'[U_EV^1=/Q3\/"0@)?-"#@SB#Y,^G7/Z5UUC?6VI6,5Y:2>9;S+N1]I M&1]#S6?K6KVWAO3D%*<9 :P]0^)'A^PNWMT>X MO&C_ -8UK'O5/4DD@$>XS5SQW%9974'Y/_?(;'JOO7HM5 M"3=T^AGB*48.+AM)7.7U/Q[H^FZC)8!+N[GB.)1:P[Q&?MZ M='?V,A>"3(!*E2"#@@@UP=W:>(O ^MZGJVG6J:EI5Y*9YXQ]].2?J,9//(QU M%=AH?B'3=6T!M7M\06Z[VG# QL!ELXZ\W_UZUKNY2RLYKJ17:.%#(P09. ,G M [UXC)/I6O:;X@U>_OX8=5GG$EG&[?.JIT48]1\H_P!T5ZQX2UI?$/ABUO&P M92OES@_WUX/Y]?H:(5.9M?<5B<(J,%)7TT?KOIY=/5%[2-7L]2>SXF;;\BG.,9]#T9CP%'\B?]@UT_P\T=]-\-+=7)+7FH-]IE8]<'[H/X<_5C1&;DTO MO%6PT*<93Z.W+\]?P7XB0_$?0[A"\,=_(H."4M689_"NCTW4(=5T^*]@658I M,X$J%&X)'(/3I7E7P^U#Q-::#/'HVB0WUL;IF:1[A4(?:N1@D=L'\:]6TZ6[ MFTZ"2_MUM[IES+$K!@A],CK12FY*[_(,90A1DXQ77O=_=T*VN:]8^';!;R_9 MUA:01@HNXY()_H:TZX/XM_\ (H0_]?B?^@O7>5:D^9HYYTTJ,9K=M_A8S9=< MLHO$$.B,S_;)H?.0;?EV\]_^ FFV'B"PU'5KW3(6D%W9G]ZCIMXSC(]1T_,5 MS5__ ,EETS_L&M_.2H/%Z_\ "->+]+\51*?(E;[+? =P1@-]4;KUU_.QU>I>(+'2]2L=/G,C7-ZVV%(TW=P,GT'/7V-4]5\9Z5 MH^J'3K@7+W(0.5AA+\'Z5S_A?/B;QUJ?B1\M:6G^B61/(ZP:]I2:>K($C,4RN7#!@W0G&./SKB[.X\0_#>%K6\L$U#0_,+?:(?O(# MZ^GT88SP#1*SMJ_(]-M;F&]M(;JW??#-&LD;8(R MI&0<'GH:EJKIMU:WNF6US8[?LLD:M$%7: N.!CMCIBK5;+8\Z2LV@HHHIB"B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (YX(KJWEMY MT#Q2H4=#T92,$?E6!X-\+KX6TJ6V+K+-+,SO(O=:V]5TNUUG39["]3?!,N#C@@ M]B/<'FKE%)12NARK3DTV]5M\C@H/"WC'28ULM)\30_8%.$%Q""\:^@RK9],9 M ^E;/ACPE'H$EQ>W-W)?:I=?ZZYD'..N!WQT[\X'3I7245*IQ3N:3Q52<7%V MUWLDK^ISFD^&YM.\5ZMK#W"/'? !8P#E<8ZU'I?A:?1_%U]J=G<1KI]\,RVN M#D/UW#MUS^#&NGHI\B)>(J.]WNK?);'-Z%X8?2]6U^ZN)8IX=4E#B+;]U(J.]WNDG\ MMCF]'\-3:9XJU?5WN(WCOL;8P#E>>]'ASPU-HFLZ[?27$, M?YYVO$WAJT\3ZUDTZ7Q-:R6,D9B=G@!D92,$'Y?0]=V:ZKP[HR^']!M=+68SB -^\*[=Q+%C MQVY-:E%$8).X5,1.I'E=DM]$D%BC\,?3@ 5T]%%.,5%61-2I*I+FDSC[K1/%\-U=C2]?M_LEQ*\ MBK..U,3P3/8^!I?#VGWJ+-S1K]:J625M+/9:VVOW,*P\'Z%9Z?;VSZ383O%&J-+);(S.0.221U-5_#?A MB7PYJFIF"XC.FW;^;% 08F]!VQ@X_ 5TM%5R1T(=>HTTW>__#G+^+?!\7B> MXTV5G5#;3?O<_P <1Y91[\#'U-=. % ' I:*:BDVR95)2BH-Z+8X#0O" M'BCP[9/::?K5@L+R&4A[.>[&?,DB3:IY.,#Z8J MW14Q@H[%U:\JNLK7]#G?&?AR;Q1HB6$-PD#+.LNYP2, $8X^M016'C,3(9=; MTYHPPW 6I!([UU-%#@F[A&O*,.2R:\U?.;3Q )T$4%J8#%@[B+O\.WR,GPSHJ^ M'_#]KIP*L\:YE=>C.>6/TST]@*Q-5\+:Q+XN;7M*U&VMY#"(=LL1?CO78T4G M!-6*C7G&;GU>_P S"TVQU_9L"[\+^+[RR?29O$5 MK-IT@VO+)!^^*YZ>_P!G0Z3I=MI\!8Q6\81 M2QY..YJW115K0YVVW=A1110(**** "BBB@ HHHH **** "BBB@ HHHH **** / "BBB@ HHHH **** /_9 end EX-101.SCH 8 ctso-20240628.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 9 ctso-20240628_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 10 ctso-20240628_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jun. 28, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 28, 2024
Entity File Number 001-36792
Entity Registrant Name CYTOSORBENTS CORPORATION
Entity Central Index Key 0001175151
Entity Tax Identification Number 98-0373793
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 305 College Road East
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 732
Local Phone Number 329-8885
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol CTSO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cytosorbents.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ctso-20240628.xsd ctso-20240628_lab.xml ctso-20240628_pre.xml tm2418904d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2418904d1_8k.htm": { "nsprefix": "ctso", "nsuri": "http://cytosorbents.com/20240628", "dts": { "schema": { "local": [ "ctso-20240628.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ctso-20240628_lab.xml" ] }, "presentationLink": { "local": [ "ctso-20240628_pre.xml" ] }, "inline": { "local": [ "tm2418904d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://cytosorbents.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2418904d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-28", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2418904d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://cytosorbents.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 20 0001104659-24-077866-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-077866-xbrl.zip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end XML 21 tm2418904d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001175151 2024-06-28 2024-06-28 iso4217:USD shares iso4217:USD shares false 0001175151 8-K 2024-06-28 CYTOSORBENTS CORPORATION DE 001-36792 98-0373793 305 College Road East Princeton NJ 08540 732 329-8885 false false false false Common stock, par value $0.001 per share CTSO NASDAQ false